<article title='Analgesic'><paragraph><template><target>Redirect</target><arg>Painkiller</arg></template><link><target>File:12-08-18-tilidin-retard.jpg</target><part>Tilidine, a brand of painkiller</part><part>thumb</part></link></paragraph><paragraph>An<space/><bold>analgesic</bold><space/>or<space/><bold>painkiller</bold><space/>is any member of the group of<space/><link><target>Pharmaceutical drug</target><part>drugs</part></link><space/>used to achieve analgesia, relief from<space/><link><target>pain</target></link>.<space/></paragraph><paragraph>Analgesic drugs act in various ways on the<space/><link><target>peripheral nervous system</target><part>peripheral</part></link><space/>and<space/><link><target>central nervous system</target><part>central</part></link><space/>nervous systems. They are distinct from<space/><link><target>anesthetic</target><trail>s</trail></link>, which reversibly eliminate<space/><link><target>sense</target><part>sensation</part></link>. Analgesics include<space/><link><target>paracetamol</target></link><space/>(known in the US as<space/><link><target>acetaminophen</target></link><space/>or simply APAP), the<space/><link><target>non-steroidal anti-inflammatory drug</target><trail>s</trail></link><space/>(NSAIDs) such as the<space/><link><target>salicylate</target><trail>s</trail></link>, and<space/><link><target>opioid</target></link><space/>drugs such as<space/><link><target>morphine</target></link><space/>and<space/><link><target>oxycodone</target></link>.</paragraph><paragraph>In choosing analgesics, the severity and response to other medication determines the choice of agent; the World Health Organization (WHO)<space/><link><target>pain ladder</target></link><extension extension_name='ref'><template><target>cite book</target><arg name="last">Anonymous<space/></arg><arg name="title">Cancer pain relief and palliative care; report of a WHO expert committee<space/></arg><arg name="series">World Health Organization Technical Report Series, 804<space/></arg><arg name="year">1990<space/></arg><arg name="publisher">World Health Organization<space/></arg><arg name="location">Geneva, Switzerland<space/></arg><arg name="isbn">92-4-120804-X<space/></arg><arg name="pages">1–75</arg></template></extension><space/>specifies mild analgesics as its first step.</paragraph><paragraph>Analgesic choice is also determined by the type of pain: For<space/><link><target>neuropathic pain</target></link>, traditional analgesics are less effective, and there is often benefit from classes of drugs that are not normally considered analgesics, such as<space/><link><target>tricyclic antidepressants</target></link><space/>and<space/><link><target>anticonvulsant</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid14623723"><template><target>cite journal</target><arg name="author"><space/>Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM<space/></arg><arg name="title"><space/>Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations<space/></arg><arg name="journal"><space/>Arch. Neurol.<space/></arg><arg name="volume"><space/>60<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1524–34<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14623723<space/></arg><arg name="doi"><space/>10.1001/archneur.60.11.1524<space/></arg><arg name="url"><space/>http://archneur.ama-assn.org/cgi/content/full/60/11/1524<space/></arg><arg name="last2"><space/>Backonja<space/></arg><arg name="last3"><space/>Rowbotham<space/></arg><arg name="last4"><space/>Allen<space/></arg><arg name="last5"><space/>Argoff<space/></arg><arg name="last6"><space/>Bennett<space/></arg><arg name="last7"><space/>Bushnell<space/></arg><arg name="last8"><space/>Farrar<space/></arg><arg name="last9"><space/>Galer<space/></arg><arg name="last10"><space/>Haythornthwaite<space/></arg><arg name="last11"><space/>Hewitt<space/></arg><arg name="last12"><space/>Loeser<space/></arg><arg name="last13"><space/>Max<space/></arg><arg name="last14"><space/>Saltarelli<space/></arg><arg name="last15"><space/>Schmader<space/></arg><arg name="last16"><space/>Stein<space/></arg><arg name="last17"><space/>Thompson<space/></arg><arg name="last18"><space/>Turk<space/></arg><arg name="last19"><space/>Wallace<space/></arg><arg name="last20"><space/>Watkins<space/></arg><arg name="last21"><space/>Weinstein<space/></arg></template></extension></paragraph><paragraph><template><target>anchor</target><arg>Etymology</arg></template></paragraph><heading level='2'>Name</heading><paragraph>The word<space/><italics>analgesic</italics><space/>derives from<space/><link><target>Greek language</target><part>Greek</part></link><space/><italics>an-</italics><space/>(<template><target>lang</target><arg>grc</arg><arg>ἀν-</arg></template>, &quot;without&quot;),<space/><italics>lgos</italics><space/>(<template><target>lang</target><arg>grc</arg><arg>ἄλγος</arg></template>, &quot;pain&quot;),<extension extension_name='ref'><template><target>cite web</target><arg name="last">Harper,D.</arg><arg name="title">Online Etymology Dictionary: Analgesia</arg><arg name="year">2001</arg><arg name="url">http://www.etymonline.com/index.php?search</arg><arg name="accessdate">December 3, 2012</arg></template></extension><space/>and<space/><italics>-ikos</italics><space/>(<template><target>lang</target><arg>grc</arg><arg>-ικος</arg></template>, forming<space/><link><target>adjective</target><trail>s</trail></link>). Such drugs were usually known as<space/><bold><link><target>anodyne</target><trail>s</trail></link></bold><space/>before the 20th century.<template><target>sfnp</target><arg>EB</arg><arg>1878</arg></template><template><target>sfnp</target><arg>EB</arg><arg>1911</arg></template></paragraph><heading level='2'>Major classes</heading><heading level='3'>Paracetamol and NSAIDs</heading><paragraph><template><target>Main</target><arg>Non-steroidal anti-inflammatory drug</arg></template></paragraph><paragraph>The exact mechanism of action of<space/><link><target>paracetamol</target><part>paracetamol/acetaminophen</part></link><space/>is uncertain but appears to act centrally in the brain rather than peripherally in nerve endings.<space/><link><target>Aspirin</target></link><space/>and the other<space/><link><target>non-steroidal anti-inflammatory drug</target><trail>s</trail></link><space/>(NSAIDs) inhibit<space/><link><target>cyclooxygenase</target><trail>s</trail></link>, leading to a decrease in<space/><link><target>prostaglandin</target></link><space/>production. In contrast to paracetamol and the opioids, this reduces not only pain but<space/><link><target>inflammation</target></link><space/>as well.<template><target>Citation needed</target><arg name="date">February 2007</arg></template></paragraph><paragraph>Paracetamol has few side-effects and is regarded as generally safe in low and infrequent doses as prescribed or per manufacturer's instructions, otherwise use can lead to potentially life-threatening<space/><link><target>paracetamol toxicity</target><part>liver damage</part></link><space/>and occasionally<space/><link><target>analgesic nephropathy</target><part>kidney damage</part></link>. Side effects include bloody or black, tarry stools, bloody or cloudy urine, fever with or without chills (not present before treatment and not caused by the condition being treated), pain in the lower back and/or side (severe and/or sharp), pinpoint red spots on the skin, skin rash, hives, or itching, sore throat (not present before treatment and not caused by the condition being treated), sores, ulcers, or white spots on the lips or in the mouth, sudden decrease in the amount of urine, unusual bleeding or bruising, unusual tiredness or weakness, yellow eyes or skin.<extension extension_name='ref'><link type='external' href='http://www.drugs.com/sfx/acetaminophen-side-effects.html'>Acetaminophen Side Effects in Detail Drugs.com</link></extension></paragraph><paragraph>While paracetamol is usually taken orally or rectally, an intravenous preparation introduced in 2002 has been shown to improve pain relief and reduce opioid consumption in the perioperative setting.</paragraph><paragraph>NSAIDs can predispose to in some patients<space/><link><target>peptic ulcer</target><trail>s</trail></link>,<space/><link><target>renal failure</target></link>,<space/><link><target>allergy</target><part>allergic reactions</part></link>, and occasionally<space/><link><target>tinnitus</target></link><space/>with excess dosage, and they can increase the risk of<space/><link><target>hemorrhage</target></link><space/>by affecting<space/><link><target>platelet</target></link><space/>function. The use of aspirin in children under 16 suffering from viral illness has been linked to<space/><link><target>Reye's syndrome</target></link>, a rare but severe liver disorder.</paragraph><heading level='3'>COX-2 inhibitors</heading><paragraph><template><target>Main</target><arg>COX-2 inhibitor</arg></template></paragraph><paragraph>These drugs have been derived from NSAIDs. The<space/><link><target>cyclooxygenase</target></link><space/>enzyme inhibited by NSAIDs was discovered to have at least 2 different versions: COX1 and COX2. Research suggested most of the adverse effects of NSAIDs to be mediated by blocking the COX1 (<link><target>Constitutive enzyme</target><part>constitutive</part></link>) enzyme, with the analgesic effects being mediated by the COX2 (<link><target>Adaptive enzyme</target><part>inducible</part></link>) enzyme. Thus, the COX2 inhibitors were developed to inhibit only the COX2 enzyme (traditional NSAIDs block both versions in general). These drugs (such as<space/><link><target>rofecoxib</target></link>,<space/><link><target>celecoxib</target></link>, and<space/><link><target>etoricoxib</target></link>) are equally effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular.<extension extension_name='ref' name="Conaghan2012"><template><target>cite journal</target><arg name="author"><space/>Conaghan PG<space/></arg><arg name="title"><space/>A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity<space/></arg><arg name="journal"><space/>Rheumatol. Int.<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1491–502<space/></arg><arg name="date"><space/>June 2012<space/></arg><arg name="pmid"><space/>22193214<space/></arg><arg name="pmc"><space/>3364420<space/></arg><arg name="doi"><space/>10.1007/s00296-011-2263-6<space/></arg><arg name="url"><space/>http://www.springerlink.com/content/851u341753405ukn/fulltext.html<space/></arg></template></extension></paragraph><paragraph>After widespread adoption of the COX-2 inhibitors, it was discovered that most of the drugs in this class increase the risk of cardiovascular events by 40% on average. This led to the withdrawal of rofecoxib and valdecoxib, and warnings on others. Etoricoxib seems relatively safe, with the risk of thrombotic events similar to that of non-coxib NSAID diclofenac.<extension extension_name='ref' name="Conaghan2012"></extension></paragraph><heading level='3'>Opioids</heading><paragraph><template><target>Main</target><arg>Opioid</arg></template></paragraph><paragraph><link><target>Morphine</target></link>, the archetypal<space/><link><target>opioid</target></link>, and various other substances (e.g.,<space/><link><target>codeine</target></link>,<space/><link><target>oxycodone</target></link>,<space/><link><target>hydrocodone</target></link>,<space/><link><target>dihydromorphine</target></link>,<space/><link><target>pethidine</target></link>) all exert a similar influence on the<space/><link><target>Cerebrum</target><part>cerebral</part></link><space/><link><target>opioid receptor</target></link><space/>system.<space/><link><target>Buprenorphine</target></link><space/>is thought to be a<space/><link><target>partial agonist</target></link><space/>of the opioid receptor, and<space/><link><target>tramadol</target></link><space/>is an opiate agonist with SNRI properties.<template><target>Citation needed</target><arg name="reason">tramadol</arg><arg name="date">February 2009</arg></template><space/><link><target>Tramadol</target></link><space/>is structurally closer to<space/><link><target>venlafaxine</target></link><space/>than to<space/><link><target>codeine</target></link><space/>and delivers analgesia by not only delivering &quot;opiate-like&quot; effects (through mild agonism of the<space/><link><target>mu receptor</target></link>) but also by acting as a weak but fast-acting<space/><link><target>serotonin releasing agent</target></link><space/>and<space/><link><target>norepinephrine reuptake inhibitor</target></link>.<extension extension_name='ref' name="pmid1596676"><template><target>cite journal</target><arg name="author"><space/>Driessen B, Reimann W<space/></arg><arg name="title"><space/>Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro<space/></arg><arg name="journal"><space/>British Journal of Pharmacology<space/></arg><arg name="volume"><space/>105<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>147–51<space/></arg><arg name="date"><space/>January 1992<space/></arg><arg name="pmid"><space/>1596676<space/></arg><arg name="pmc"><space/>1908625<space/></arg><arg name="doi"><space/>10.1111/j.1476-5381.1992.tb14226.x<space/></arg><arg name="url"><space/></arg><arg name="last2"><space/>Reimann<space/></arg></template></extension><extension extension_name='ref' name="pmid9389855"><template><target>cite journal</target><arg name="author"><space/>Bamigbade TA, Davidson C, Langford RM, Stamford JA<space/></arg><arg name="title"><space/>Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus<space/></arg><arg name="journal"><space/>British Journal of Anaesthesia<space/></arg><arg name="volume"><space/>79<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>352–6<space/></arg><arg name="date"><space/>September 1997<space/></arg><arg name="pmid"><space/>9389855<space/></arg><arg name="doi"><space/>10.1093/bja/79.3.352<space/></arg><arg name="url"><space/>http://bja.oxfordjournals.org/cgi/pmidlookup?view</arg><arg name="last2"><space/>Davidson<space/></arg><arg name="last3"><space/>Langford<space/></arg><arg name="last4"><space/>Stamford<space/></arg></template><template><target>dead link</target><arg name="date">September 2015</arg></template></extension><extension extension_name='ref' name="pmid9671098"><template><target>cite journal</target><arg name="author"><space/>Reimann W, Schneider F<space/></arg><arg name="title"><space/>Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine<space/></arg><arg name="journal"><space/>European Journal of Pharmacology<space/></arg><arg name="volume"><space/>349<space/></arg><arg name="issue"><space/>2–3<space/></arg><arg name="pages"><space/>199–203<space/></arg><arg name="date"><space/>May 1998<space/></arg><arg name="pmid"><space/>9671098<space/></arg><arg name="doi"><space/>10.1016/S0014-2999(98)00195-2<space/></arg><arg name="last2"><space/>Schneider<space/></arg></template></extension><extension extension_name='ref' name="pmid12354291"><template><target>cite journal</target><arg name="author"><space/>Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C, Mennini T<space/></arg><arg name="title"><space/>p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro<space/></arg><arg name="journal"><space/>Journal of Neurochemistry<space/></arg><arg name="volume"><space/>82<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1435–43<space/></arg><arg name="date"><space/>September 2002<space/></arg><arg name="pmid"><space/>12354291<space/></arg><arg name="doi"><space/>10.1046/j.1471-4159.2002.01073.x<space/></arg><arg name="last2"><space/>Moia<space/></arg><arg name="last3"><space/>Pirona<space/></arg><arg name="last4"><space/>Ceglia<space/></arg><arg name="last5"><space/>Reyes-Parada<space/></arg><arg name="last6"><space/>Scorza<space/></arg><arg name="last7"><space/>Mennini<space/></arg></template></extension><space/>Tapentadol, with some structural similarities to tramadol, presents what is believed to be a novel drug working through two (and possibly three) different modes of action in the fashion of both a traditional opioid and as a SNRI. The effects of serotonin and<space/><link><target>norepinephrine reuptake inhibitor</target><part>norepinephrine</part></link><space/>on pain, while not completely understood, have had causal links established and drugs in the SNRI class are commonly used in conjunction with opioids (especially tapentadol and tramadol) with greater success in pain relief. Dosing of all opioids may be limited by opioid toxicity (confusion, respiratory depression,<space/><link><target>myoclonus</target><part>myoclonic jerks</part></link><space/>and pinpoint pupils), seizures (<link><target>tramadol</target></link>), but opioid-tolerant individuals usually have higher dose ceilings than patients without tolerance.<space/><template><target>Citation needed</target><arg name="date">April 2010</arg></template></paragraph><paragraph>Opioids, while very effective analgesics, may have some unpleasant side-effects. Patients starting morphine may experience<space/><link><target>nausea</target></link><space/>and<space/><link><target>vomiting</target></link><space/>(generally relieved by a short course of<space/><link><target>antiemetic</target><trail>s</trail></link><space/>such as<space/><link><target>phenergan</target></link>).<space/><link><target>Pruritus</target></link><space/>(itching) may require switching to a different opioid.<space/><link><target>Constipation</target></link><space/>occurs in almost all patients on opioids, and<space/><link><target>laxative</target><trail>s</trail></link><space/>(<link><target>lactulose</target></link>,<space/><link><target>macrogol</target></link>-containing or co-danthramer) are typically co-prescribed.<extension extension_name='ref' name="oxford">Oxford Textbook of Palliative Medicine, 3rd ed. (Doyle D, Hanks G, Cherney I and Calman K, eds. Oxford University Press, 2004).</extension></paragraph><paragraph>When used appropriately, opioids and similar<space/><link><target>narcotic</target></link><space/>analgesics are otherwise safe and effective, however risks such as addiction and the body's becoming used to the drug (tolerance) can occur. The effect of tolerance means that frequent use of the drug may result in its diminished effect so, when safe to do so, the dosage may need to be increased to maintain effectiveness. This may be of particular concern regarding patients suffering with chronic pain.<template><target>Citation needed</target><arg name="date">April 2010</arg></template></paragraph><heading level='3'>Flupirtine</heading><paragraph><link><target>Flupirtine</target></link><space/>is a centrally acting K+ channel opener with weak<space/><link><target>NMDA antagonist</target></link><space/>properties.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG<space/></arg><arg name="title"><space/>Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication<space/></arg><arg name="journal"><space/>J Neural Transm<space/></arg><arg name="volume"><space/>106<space/></arg><arg name="issue"><space/>9–10<space/></arg><arg name="pages"><space/>857–67<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10599868<space/></arg><arg name="doi"><space/>10.1007/s007020050206<space/></arg><arg name="last2"><space/>Bleich<space/></arg><arg name="last3"><space/>Wiltfang<space/></arg><arg name="last4"><space/>Maler<space/></arg><arg name="last5"><space/>Parsons<space/></arg></template></extension><space/>It is used in Europe for moderate to strong pain and<space/><link><target>migraine</target></link><space/>and its muscle-relaxant properties. It has no<space/><link><target>anticholinergic</target></link><space/>properties and is believed to be devoid of any activity on dopamine, serotonin, or histamine receptors. It is not addictive, and tolerance usually does not develop.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Klawe C, Maschke M<space/></arg><arg name="title"><space/>Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound<space/></arg><arg name="journal"><space/>Expert opinion on pharmacotherapy<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1495–500<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19505216<space/></arg><arg name="doi"><space/>10.1517/14656560902988528<space/></arg><arg name="last2"><space/>Maschke<space/></arg></template></extension><space/>However, tolerance may develop in single cases.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Stoessel C, Heberlein A, Hillemacher T, Bleich S, Kornhuber J<space/></arg><arg name="title"><space/>Positive reinforcing effects of flupirtine—two case reports<space/></arg><arg name="journal"><space/>Prog. Neuropsychopharmacol. Biol. Psychiatry<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1120–1<space/></arg><arg name="date"><space/>August 2010<space/></arg><arg name="pmid"><space/>20362025<space/></arg><arg name="doi"><space/>10.1016/j.pnpbp.2010.03.031<space/></arg><arg name="last2"><space/>Heberlein<space/></arg><arg name="last3"><space/>Hillemacher<space/></arg><arg name="last4"><space/>Bleich<space/></arg><arg name="last5"><space/>Kornhuber<space/></arg></template></extension></paragraph><heading level='3'>Specific agents</heading><paragraph>In patients with chronic or neuropathic pain, various other substances may have analgesic properties.<space/><link><target>Tricyclic antidepressant</target><trail>s</trail></link>, especially<space/><link><target>amitriptyline</target></link>, have been shown to improve pain in what appears to be a central manner.<template><target>Citation needed</target><arg name="date">April 2010</arg></template><space/>Nefopam is used in Europe for pain relief with concurrent opioids. The exact mechanism of<space/><link><target>carbamazepine</target></link>,<space/><link><target>gabapentin</target></link>, and<space/><link><target>pregabalin</target></link><space/>is similarly unclear, but these<space/><link><target>anticonvulsant</target><trail>s</trail></link><space/>are used to treat neuropathic pain with differing degrees of success. Anticonvulsants are most commonly used for neuropathic pain as their mechanism of action tends to inhibit pain sensation.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Drug Treatment in Urology</arg><arg name="publisher">John Wiley & Sons, 2008</arg><arg name="author">Ian Eardley, Peter Whelan, Roger Kirby, Anthony Schaeffer</arg><arg name="page">65</arg><arg name="chapter">Drugs Used In The Treatment Of Interstitial Cystitis</arg></template></extension></paragraph><heading level='2'>Specific forms and uses</heading><heading level='3'>Combinations</heading><paragraph>Analgesics are frequently used in combination, such as the<space/><link><target>paracetamol</target></link><space/>and<space/><link><target>codeine</target></link><space/>preparations found in many non-prescription pain relievers. They can also be found in combination with vasoconstrictor drugs such as<space/><link><target>pseudoephedrine</target></link><space/>for<space/><link><target>Paranasal sinus</target><part>sinus</part></link>-related preparations, or with<space/><link><target>antihistamine</target></link><space/>drugs for allergy sufferers.</paragraph><paragraph>While the use of paracetamol, aspirin,<space/><link><target>ibuprofen</target></link>,<space/><link><target>naproxen</target></link>, and other<space/><link><target>NSAIDS</target></link><space/>concurrently with weak to mid-range opiates (up to about the hydrocodone level) has been said to show beneficial synergistic effects by combatting pain at multiple sites of action,<extension extension_name='ref' name="pmid12148679"><template><target>cite journal</target><arg name="author"><space/>Mehlisch DR<space/></arg><arg name="title"><space/>The efficacy of combination analgesic therapy in relieving dental pain<space/></arg><arg name="journal"><space/>J Am Dent Assoc<space/></arg><arg name="volume"><space/>133<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>861–71<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12148679<space/></arg><arg name="doi"><space/>10.14219/jada.archive.2002.0300<space/></arg><arg name="url"><space/>http://jada.ada.org/cgi/content/full/133/7/861<space/></arg></template><template><target>dead link</target><arg name="date">September 2015</arg></template></extension><space/>several combination analgesic products have been shown to have few efficacy benefits when compared to similar doses of their individual components. Moreover, these combination analgesics can often result in significant adverse events, including accidental overdoses, most often due to confusion that arises from the multiple (and often non-acting) components of these combinations.<extension extension_name='ref' name="nps01"><template><target>cite journal</target><arg name="author">Murnion B<space/></arg><arg name="title">Combination analgesics in adults<space/></arg><arg name="journal">Australian Prescriber<space/></arg><arg name="issue">33<space/></arg><arg name="pages">113–5<space/></arg><arg name="url">http://www.australianprescriber.com/magazine/33/4/113/5<space/></arg><arg name="accessdate">12 August 2010</arg></template></extension></paragraph><heading level='3'>Topical or systemic</heading><paragraph>Topical analgesia is generally recommended to avoid systemic side-effects. Painful joints, for example, may be treated with an<space/><link><target>ibuprofen</target></link>- or<space/><link><target>diclofenac</target></link>-containing gel (The labeling for topical diclofenac has been updated to warn about drug-induced hepatotoxicity.<extension extension_name='ref'><link type='external' href='http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm193047.htm'>Voltaren Gel (diclofenac sodium topical gel) 1% Hepatic Effects Labeling Changes</link></extension>);<space/><link><target>capsaicin</target></link><space/>also is used<space/><link><target>topical cream</target><part>topical</part><trail>ly</trail></link>.<space/><link><target>Lidocaine</target></link>, an<space/><link><target>anesthetic</target></link>, and<space/><link><target>glucocorticoid</target><part>steroids</part></link><space/>may be injected into painful joints for longer-term pain relief.<space/><link><target>Lidocaine</target></link><space/>is also used for painful<space/><link><target>mouth sore</target><trail>s</trail></link><space/>and to numb areas for<space/><link><target>dentistry</target><part>dental</part></link><space/>work and minor medical procedures. In February 2007 the FDA notified consumers and healthcare professionals of the potential hazards of the use of topical anesthetics. These topical anesthetics contain anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel.<extension extension_name='ref'><link type='external' href='http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054718.htm'></link><space/><template><target>wayback</target><arg name="url">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054718.htm<space/></arg><arg name="date">20101019055341<space/></arg></template></extension></paragraph><heading level='3'>Psychotropic agents</heading><paragraph><link><target>Tetrahydrocannabinol</target></link><space/>(THC) and some other<space/><link><target>cannabinoid</target><trail>s</trail></link>, either from the<space/><italics><link><target>Cannabis sativa</target></link></italics><space/>plant or synthetic, have analgesic properties, although the use of cannabis derivatives is currently illegal in many countries. A recent study finds that inhaled cannabis is effective in alleviating neuropathy and pain resulting from, e.g., spinal injury and multiple sclerosis.<extension extension_name='ref'>CMCR:<space/><italics>CMCR Report February 17th</italics>, California, 2010. http://www.cmcr.ucsd.edu/CMCR_REPORT_FEB17.pdf</extension>Other psychotropic analgesic agents include<space/><link><target>ketamine</target></link><space/>(an NMDA receptor antagonist),<space/><link><target>clonidine</target></link><space/>and other<space/><xhtml:sub>2</xhtml:sub>-adrenoreceptor agonists, and<space/><link><target>mexiletine</target></link><space/>and other local anaesthetic analogues.</paragraph><heading level='3'>Atypical, adjuvant analgesics &amp; potentiators</heading><paragraph>Drugs that have been introduced for uses other than analgesics are also used in pain management. Both first-generation (such as<space/><link><target>amitriptyline</target></link>) and newer anti-depressants (such as<space/><link><target>duloxetine</target></link>) are used alongside NSAIDs and opioids for pain involving nerve damage and similar problems. Other agents directly potentiate the effects of analgesics, such as using<space/><link><target>hydroxyzine</target></link>,<space/><link><target>promethazine</target></link>,<space/><link><target>carisoprodol</target></link>, or<space/><link><target>tripelennamine</target></link><space/>to increase the pain-killing ability of a given dose of opioid analgesic.</paragraph><paragraph>Adjuvant analgesics, also called atypical analgesics, include<space/><link><target>nefopam</target></link>,<space/><link><target>orphenadrine</target></link>,<space/><link><target>pregabalin</target></link>,<space/><link><target>gabapentin</target></link>,<space/><link><target>cyclobenzaprine</target></link>,<space/><link><target>scopolamine</target></link>, and other drugs possessing anticonvulsant, anticholinergic, and/or antispasmodic properties, as well as many other drugs with CNS actions. These drugs are used along with analgesics to modulate and/or modify the action of opioids when used against pain, especially of neuropathic origin.</paragraph><paragraph><link><target>Dextromethorphan</target></link><space/>has been noted to slow the development of tolerance to opioids and exert additional analgesia by acting upon the<space/><link><target>NMDA</target></link><space/>receptors;<template><target>Citation needed</target><arg name="date">July 2014</arg></template><space/>some analgesics such as<space/><link><target>methadone</target></link><space/>and<space/><link><target>ketobemidone</target></link><space/>and perhaps<space/><link><target>piritramide</target></link><space/>have intrinsic NMDA action.<template><target>Citation needed</target><arg name="date">July 2014</arg></template></paragraph><paragraph>High-alcohol<space/><link><target>liquor</target></link>, two forms of which found in the US Pharmacopoeia up until 1916 and in common use by physicians well into the 1930s, has been used in the past as an agent for dulling pain, due to the<space/><link><target>Central nervous system</target><part>CNS</part></link><space/>depressant effects of<space/><link><target>Ethanol</target><part>ethyl alcohol</part></link>, a notable example being the<space/><link><target>American Civil War</target></link>. However, the ability of alcohol to relieve severe pain is likely inferior to many analgesics used today (e.g., morphine, codeine). As such, in general, the idea of alcohol for analgesia is considered a primitive practice in virtually all industrialized countries today.</paragraph><paragraph>The use of<space/><link><target>adjuvant</target></link><space/>analgesics is an important and growing part of the pain-control field and new discoveries are made practically every year. Many of these drugs combat the side-effects of opioid analgesics, an added bonus. For example,<space/><link><target>antihistamines</target></link><space/>including orphenadrine combat the release of histamine caused by many opioids. Stimulants such as<space/><link><target>methylphenidate</target></link>,<space/><link><target>caffeine</target></link>,<space/><link><target>ephedrine</target></link>,<space/><link><target>dextroamphetamine</target></link>,<space/><link><target>methamphetamine</target></link>, and<space/><link><target>cocaine</target></link><space/>work against heavy sedation and may elevate mood in distressed patients as do the antidepressants.<template><target>Citation needed</target><arg name="date">July 2014</arg></template><space/>The use of medicinal<space/><link><target>cannabis</target></link><space/>remains a debated issue.</paragraph><heading level='2'>Comparison of available agents</heading><table class="wikitable collapsible collapsed" style="width:100%"><tablecaption><xhtml:big>Comparison of different analgesics</xhtml:big></tablecaption><tablerow><tablehead>Generic name (INN)</tablehead><tablehead>Physicochemistry<extension extension_name='ref' name="MD"><template><target>cite web</target><arg name="title">Martindale: The Complete Drug Reference</arg><arg name="publisher">Pharmaceutical Press</arg><arg name="work">Medicines Complete</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://www.medicinescomplete.com/mc/martindale/current/</arg><arg name="editor">Brayfield, A</arg></template></extension></tablehead><tablehead>Mechanism of action<extension extension_name='ref' name="GG"></extension></tablehead><tablehead>Routes of administration<xhtml:br></xhtml:br><extension extension_name='ref' name="GG"></extension><extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="BNF"></extension></tablehead><tablehead style="width:100px;">Pharmacokinetics<extension extension_name='ref' name="MD"></extension></tablehead><tablehead>Indications<xhtml:br></xhtml:br><extension extension_name='ref' name="GG"></extension><extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="BNF"></extension></tablehead><tablehead>Major safety concerns<xhtml:br></xhtml:br><extension extension_name='ref' name="GG"><template><target>cite book</target><arg name="last1">Brunton<space/></arg><arg name="first1">L<space/></arg><arg name="last2">Chabner<space/></arg><arg name="first2">B<space/></arg><arg name="last3">Knollman<space/></arg><arg name="first3">B<space/></arg><arg name="title"><space/>Goodman and Gilman's The Pharmacological Basis of Therapeutics<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="publisher"><space/>McGraw-Hill Professional<space/></arg><arg name="isbn"><space/>978-0-07-162442-8<space/></arg><arg name="edition"><space/>12th<space/></arg><arg name="location"><space/>New York<space/></arg></template></extension><extension extension_name='ref' name="AMH"><template><target>cite book</target><arg name="title">Australian Medicines Handbook<space/></arg><arg name="year">2013<space/></arg><arg name="publisher">The Australian Medicines Handbook Unit Trust<space/></arg><arg name="isbn">978-0-9805790-9-3<space/></arg><arg name="edition">2013<space/></arg><arg name="location">Adelaide<space/></arg><arg name="editor-last">Rossi<space/></arg><arg name="editor-first">S</arg></template></extension><extension extension_name='ref' name="BNF"><template><target>cite book</target><arg name="author">Joint Formulary Committee<space/></arg><arg name="title">British National Formulary (BNF)<space/></arg><arg name="year">2013<space/></arg><arg name="isbn">978-0-85711-084-8<space/></arg><arg name="edition">65<space/></arg><arg name="location"><space/>London, UK<space/></arg><arg name="publisher">Pharmaceutical Press</arg></template></extension></tablehead></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold><xhtml:big><link><target>Non-steroidal anti-inflammatory agents</target></link></xhtml:big></bold></tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Unselective agents</bold></tablecell></tablerow><tablerow><tablecell><link><target>Aceclofenac</target></link></tablecell><tablecell>Comes in betadex salt and free acid forms; practically insoluble in water, soluble in many organic solvents; degrades on contact with light; phenylacetic acid derivative.</tablecell><tablecell>As per ibuprofen.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 99%; half-life = 4 hours; metabolised to diclofenac (minor); excretion = urine (67%).</tablecell><tablecell>As per ibuprofen.</tablecell><tablecell>As per ibuprofen.</tablecell></tablerow><tablerow><tablecell><link><target>Acemetacin</target></link></tablecell><tablecell>Comes in free form; practically insoluble in water, soluble in certain organic solvents; degrades upon contact with light. Chemically related to<space/><link><target>indometacin</target></link></tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Slightly metabolised to<space/><link><target>indometacin</target></link>.</tablecell><tablecell>Rheumatoid arthritis, osteoarthritis and lower back pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Amfenac</target></link></tablecell><tablecell>No available data.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Pain and inflammation.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Aminophenazone</target></link></tablecell><tablecell>Related to phenylbutazone.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal and joint disorders.</tablecell><tablecell>Agranulocytosis and cancer.</tablecell></tablerow><tablerow><tablecell><link><target>Ampiroxicam</target></link></tablecell><tablecell>Related to piroxicam.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell><link><target>Rheumatoid arthritis</target></link><space/>and<space/><link><target>osteoarthritis</target></link>.</tablecell><tablecell>Photosensitivity and other AEs typical of NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Amtolmetin guacil</target></link></tablecell><tablecell>Prodrug to<space/><link><target>tolmetin</target></link>.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Aspirin</target></link></tablecell><tablecell>Comes in free form, aluminium and lysine salt forms; fairly insoluble in water (1 in 300); highly soluble (1 in 5) in alcohol; degrades on contact with air. Salicylate.</tablecell><tablecell>Irreversibly inhibits<space/><link><target>COX-1</target></link><space/>and<space/><link><target>COX-2</target></link>; hence inhibiting prostaglandin synthesis.</tablecell><tablecell>PO, IM, IV, rectal</tablecell><tablecell>Bioavailability = 80100%; protein binding = 2595% (inversely dependent on plasma concentration); half life = 23 hours, 1530 hours (higher doses); excretion = 80100%.<extension extension_name='ref' name="AMSR"><template><target>cite web</target><arg name="title">Zorprin, Bayer Buffered Aspirin (aspirin) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">6 April 2014</arg><arg name="url">http://reference.medscape.com/drug/zorprin-bayer-buffered-aspirin-343279#showall</arg></template></extension></tablecell><tablecell>Blood thining; mild-to-moderate pain; fever;<space/><link><target>rheumatic fever</target></link>; migraine;<space/><link><target>rheumatoid arthritis</target></link>;<space/><link><target>Kawasaki's disease</target></link></tablecell><tablecell>GI bleeds; ulcers;<space/><link><target>reye syndrome</target></link>; nephrotoxicity; blood dyscrasias (rarely);<space/><link><target>Stevens-Johnson syndrome</target></link><space/>(uncommon/rare)</tablecell></tablerow><tablerow><tablecell><link><target>Azapropazone</target></link></tablecell><tablecell>Comes in free form; fairly insoluble in water and chloroform, soluble in ethanol; phenylbutazone.</tablecell><tablecell>As per ibuprofen.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>No data available.</tablecell><tablecell>Rheumatoid arthritis; gout; ankylosing spondylitis.</tablecell><tablecell>As per ibuprofen.</tablecell></tablerow><tablerow><tablecell><link><target>Bendazac</target></link></tablecell><tablecell>Comes in free acid and lysine salt forms. Chemically related to<space/><link><target>indometacin</target></link>.</tablecell><tablecell>As per acetametacin.</tablecell><tablecell>Topical, ophthalmologic.</tablecell><tablecell>N/A</tablecell><tablecell>Skin conditions and<space/><link><target>cataract</target><trail>s</trail></link>.</tablecell><tablecell>Hepatotoxicity reported.</tablecell></tablerow><tablerow><tablecell><link><target>Benorilate</target></link></tablecell><tablecell>Aspirin-paracetamol ester. Practically insoluble in water, sparingly soluble in ethanol and methanol, soluble in acetone and chloroform.</tablecell><tablecell>As per aspirin and paracetamol.</tablecell><tablecell>PO.</tablecell><tablecell>Unavailable.</tablecell><tablecell>Osteoarthritis; rheumatoid arthritis; soft-tissue rheumatism; mild-moderate pain and fever.</tablecell><tablecell>As per aspirin and paracetamol.</tablecell></tablerow><tablerow><tablecell><link><target>Benzydamine</target></link></tablecell><tablecell>Comes in free acid form; freely soluble in water.</tablecell><tablecell>As above.</tablecell><tablecell>Topical, PO, rectal, spray and vaginal.</tablecell><tablecell>No data available.</tablecell><tablecell>Musculoskeletal disorders; soft-tissue disorders; sore throat.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Bromfenac</target></link></tablecell><tablecell>Comes in free acid form; phenylacetic acid derivative.</tablecell><tablecell>Reversible COX-1/COX-2 inhibitor.</tablecell><tablecell>Ophthalmologic.</tablecell><tablecell>N/A</tablecell><tablecell>Postoperative pain and inflammation.</tablecell><tablecell>Corneal ulceration.</tablecell></tablerow><tablerow><tablecell><link><target>Bufexamac</target></link></tablecell><tablecell>Comes in free acid form; practically insoluble in water, soluble in a few organic solvents; degrades upon contact with light.</tablecell><tablecell>Reversible COX-1/COX-2 inhibition.</tablecell><tablecell>Topical.</tablecell><tablecell>No data.</tablecell><tablecell>Skin disorders.</tablecell><tablecell>As per other topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Carbasalate</target></link></tablecell><tablecell>Comes in calcium salt form; fairly soluble in water.</tablecell><tablecell>Is metabolised to aspirin and urea. As per aspirin.</tablecell><tablecell>Oral.</tablecell><tablecell>No data.</tablecell><tablecell>Used for thromboembolic disorders.</tablecell><tablecell>As per ibuprofen.</tablecell></tablerow><tablerow><tablecell><link><target>Clonixin</target></link></tablecell><tablecell>Comes in free acid and lysine salt forms.</tablecell><tablecell>Reversible COX-1/COX-2 inhibition.</tablecell><tablecell>PO, IM, IV, rectal.</tablecell><tablecell>No data.</tablecell><tablecell>Pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Dexibuprofen</target></link></tablecell><tablecell>D-isomer of<space/><link><target>ibuprofen</target></link>. Propionic acid derivative.</tablecell><tablecell>As per diclofenac.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = ?; protein binding = 99%; metabolism = hepatic via carboxylation and hydroxylation; half-life = 1.83.5 hours; excretion = Urine (90%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Seractil 300mg Film-Coated Tablets – Summary of Product Characteristics</arg><arg name="work">electronic Medicines Compendium</arg><arg name="publisher">Genus Pharmaceuticals</arg><arg name="date">30 September 2005</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://www.medicines.org.uk/emc/medicine/16949/SPC/Seractil+300mg+Film-Coated+Tablets/</arg></template></extension></tablecell><tablecell>Osteoarthritis; mild-moderate pain and menstrual pain.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Derry S, Best J, Moore RA<space/></arg><arg name="title"><space/>Single dose oral dexibuprofen [S(+)-ibuprofen] for acute postoperative pain in adults<space/></arg><arg name="journal"><space/>The Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="pages"><space/>CD007550<space/></arg><arg name="date"><space/>October 2013<space/></arg><arg name="pmid"><space/>24151035<space/></arg><arg name="doi"><space/>10.1002/14651858.CD007550.pub3<space/></arg><arg name="url"><space/>http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007550.pub3/pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="last2"><space/>Best<space/></arg><arg name="last3"><space/>Moore<space/></arg></template></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Diclofenac</target></link></tablecell><tablecell>Comes in sodium, potassium and diethylamine (topically used as a gel) salt forms; sparingly soluble in water but soluble in ethanol. Unstable in the presence of light and air. Indole acetic acid derivative.</tablecell><tablecell>Reversible COX-1/COX-2 inhibitor.</tablecell><tablecell>PO and topical.</tablecell><tablecell>Bioavailability = 5060%; protein binding = 9999.8%; hepatic metabolism; half-life = 1.22 hours; excretion = urine (5070%), faeces (3035%)</tablecell><tablecell><link><target>Rheumatoid arthritis</target></link>;<space/><link><target>osteoarthritis</target></link>; inflammatory pain (e.g. period pain); local pain/inflammation (as a gel);<space/><link><target>actinic keratoses</target></link>; heavy menstrual bleeding</tablecell><tablecell>As per aspirin, except without reye syndrome and with the following additions:<space/><link><target>myocardial infarction</target><trail>s</trail></link>,<space/><link><target>strokes</target></link><space/>and<space/><link><target>hypertension</target></link>. More prone to causing these AEs compared to the other non-selective NSAIDs.<extension extension_name='ref' name="card"><template><target>cite web</target><arg name="title">Cardiovascular safety of Cox-2 inhibitors and non-selective NSAIDs<space/></arg><arg name="work">MHRA<space/></arg><arg name="date">26 July 2013<space/></arg><arg name="accessdate">7 April 2014<space/></arg><arg name="url">http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20140413144556/http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/<space/></arg><arg name="archivedate">April 13, 2014<space/></arg></template></extension></tablecell></tablerow><tablerow><tablecell><link><target>Diethylamine salicylate</target></link></tablecell><tablecell>Freely soluble in water; degrades upon contact with light and iron.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A.</tablecell><tablecell>Rheumatic and musculoskeletal pain.</tablecell><tablecell>As per other topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Diflunisal</target></link></tablecell><tablecell>Comes in free acid and<space/><link><target>arginine</target></link><space/>salt forms; practically insoluble in water, soluble in ethanol; degrades upon contact with light.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IM, IV.</tablecell><tablecell>Bioavailability = 80100%; protein binding &gt; 99%; volume of distribution = 0.11 L/kg; hepatic metabolism; half-life = 812 hours; excretion = urine (90%), faeces (<extension extension_name='5%).&lt;ref' name="MD"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">(diflunisal) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://reference.medscape.com/drug/diflunisal-343285#showall</arg></template></extension></tablecell><tablecell>Pain; osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Epirizole</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell><link><target>Rheumatoid arthritis</target></link>.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Ethenzamide</target></link></tablecell><tablecell>Comes in free form; salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal pain; fever.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Etofenamate</target></link></tablecell><tablecell>Liquid; practically insoluble in water, miscible with ethyl acetate and methanol.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal, joint and soft-tissue disorders.</tablecell><tablecell>As per topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Felbinac</target></link></tablecell><tablecell>Comes in free and<space/><link><target>diisopropanolamine</target></link><space/>salt forms; practically insoluble in water and ethanol, soluble in methanol.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A</tablecell><tablecell>Musculoskeletal pain and soft tissue injuries.</tablecell><tablecell>As per topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Fenbufen</target></link></tablecell><tablecell>Comes as free acid; fairly insoluble in most solvents (including water); propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 99%; half-life = 1017 hours.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Fenoprofen</target></link></tablecell><tablecell>Comes in calcium salt; fairly insoluble in water and chloroform and fairly soluble in alcohol; sensitive to degradation by air. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = ?; protein binding = 99%; hepatic metabolism; excretion = urine, faeces.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Nalfon (fenoprofen) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://reference.medscape.com/drug/nalfon-fenoprofen-343287#showall</arg></template></extension></tablecell><tablecell>Pain; rheumatoid arthritis and osteoarthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Fentiazac</target></link></tablecell><tablecell>Comes in free form and calcium salt; acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Fepradinol</target></link></tablecell><tablecell>Comes in free acid and hydrochloride salt forms.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A</tablecell><tablecell>Local inflammatory response.</tablecell><tablecell>As per other topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Feprazone</target></link></tablecell><tablecell>Comes in free acid and piperazine salt forms. Phenylbutazone.</tablecell><tablecell>As above.</tablecell><tablecell>Rectal, topical.</tablecell><tablecell>Not available.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Floctafenine</target></link></tablecell><tablecell>Comes in free acid form; anthranilic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>Oral.</tablecell><tablecell>Extensively metabolised by the liver; half-life = 8 hours; excretion = urinary and biliary.</tablecell><tablecell>Short-term relief from pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Flufenamic acid</target></link></tablecell><tablecell>Comes in free acid form and aluminium salt form; anthranilic acid.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A</tablecell><tablecell>Soft tissue inflammation and pain.</tablecell><tablecell>Topical effects.</tablecell></tablerow><tablerow><tablecell><link><target>Flurbiprofen</target></link></tablecell><tablecell>Comes in sodium salt and free acid forms; fairly insoluble in water but soluble in ethanol; sensitive to degradation by air. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IM, IV, ophthalmologic.</tablecell><tablecell>Bioavailability = 96% (oral); protein binding &gt; 99%; volume of distribution = 0.12 L/kg; excretion = urine (70%).<extension extension_name='ref' name="saudi"><template><target>cite journal</target><arg name="author"><space/>Abdel-Aziz AA, Al-Badr AA, Hafez GA<space/></arg><arg name="title"><space/>Flurbiprofen<space/></arg><arg name="journal"><space/>Profiles of Drug Substances, Excipients, and Related Methodology<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="pages"><space/>113–81<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22469318<space/></arg><arg name="doi"><space/>10.1016/B978-0-12-397220-0.00004-0<space/></arg><arg name="url"><space/>https://www.researchgate.net/profile/Abdullah_Al-Badr2/publication/223981944_Flurbiprofen/file/3deec52b2c9d2d49cb.pdfU0DP-SnwSmBLshnw<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="last2"><space/>Al-Badr<space/></arg><arg name="last3"><space/>Hafez<space/></arg><arg name="series"><space/>Profiles of Drug Substances, Excipients and Related Methodology<space/></arg><arg name="isbn"><space/>9780123972200<space/></arg></template></extension></tablecell><tablecell>Ophthalmologic:<space/><link><target>Vernal keratoconjunctivitis</target></link>; postoperative ocular swelling; herpetic stromal keratitis, excimer laser photorefractive keratectomy; ocular gingivitis. Systemic use:<space/><link><target>rheumatoid arthritis</target></link>;<space/><link><target>osteoarthritis</target></link>.<extension extension_name='ref' name="saudi"></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Glucametacin</target></link></tablecell><tablecell>Indometacin derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal, joint, peri-articular and soft-tissue disorders.</tablecell><tablecell>As per other systemic NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Ibuprofen</target></link></tablecell><tablecell>Comes in lysine salt and free acid forms; practically insoluble in water, but soluble in ethanol,<space/><link><target>acetone</target></link>,<space/><link><target>methanol</target></link>,<space/><link><target>dichloromethane</target></link><space/>and<space/><link><target>chloroform</target></link>. Degrades in the presence of air. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IV, topical</tablecell><tablecell>Bioavailability = 80100%; protein binding = 9099%; hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link><space/>and<space/><link><target>CYP2C19</target></link>-mediated oxidation; excretion = Urine (5060%), faeces.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Smith HS, Voss B<space/></arg><arg name="title"><space/>Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>72<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>327–37<space/></arg><arg name="date"><space/>February 2012<space/></arg><arg name="pmid"><space/>22316349<space/></arg><arg name="doi"><space/>10.2165/11599230-000000000-00000<space/></arg><arg name="last2"><space/>Voss<space/></arg></template></extension></tablecell><tablecell>Pain; fever; inflammatory illness;<space/><link><target>rheumatoid arthritis</target></link>;<space/><link><target>osteoarthritis</target></link>; heavy menstrual bleeding;<space/><link><target>patent ductus arteriosus</target></link>.<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Neumann R, Schulzke SM, Bührer C<space/></arg><arg name="title"><space/>Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis<space/></arg><arg name="journal"><space/>Neonatology<space/></arg><arg name="volume"><space/>102<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>9–15<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22414850<space/></arg><arg name="doi"><space/>10.1159/000335332<space/></arg><arg name="last2"><space/>Schulzke<space/></arg><arg name="last3"><space/>Bührer<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Johnston PG, Gillam-Krakauer M, Fuller MP, Reese J<space/></arg><arg name="title"><space/>Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit<space/></arg><arg name="journal"><space/>Clinics in Perinatology<space/></arg><arg name="volume"><space/>39<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>111–36<space/></arg><arg name="date"><space/>March 2012<space/></arg><arg name="pmid"><space/>22341541<space/></arg><arg name="pmc"><space/>3598606<space/></arg><arg name="doi"><space/>10.1016/j.clp.2011.12.002<space/></arg><arg name="url"><space/>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598606/pdf/nihms443933.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="last2"><space/>Gillam-Krakauer<space/></arg><arg name="last3"><space/>Fuller<space/></arg><arg name="last4"><space/>Reese<space/></arg></template></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Imidazole salicylate</target></link></tablecell><tablecell>Comes in free form. Salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal, topical.</tablecell><tablecell>Not available.</tablecell><tablecell>Muscular and rheumatic pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Indometacin</target></link></tablecell><tablecell>Comes in free acid and sodium salt forms; practically insoluble in water and most solvents; sensitive to degradation by light. Acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IV, rectal</tablecell><tablecell>Bioavailability = 100% (oral); protein binding = 90%; hepatic metabolism; excretion = urine (60%), faeces (33%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Arthrexin Indomethacin PRODUCT INFORMATION</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Alphapharm Pty Limited</arg><arg name="date">14 October 2011</arg><arg name="accessdate">7 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell><link><target>Rheumatoid arthritis</target></link>;<space/><link><target>osteoarthritis</target></link>;<space/><link><target>gout</target></link>;<space/><link><target>ankylosing spondylitis</target></link>; period pain; patent ductus arteriosus.<extension extension_name='ref' name="AMH"></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Isonixin</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal and topical.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal and joint disorders.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Kebuzone</target></link></tablecell><tablecell>Comes in free and sodium salt form; phenylbutazone derivative.</tablecell><tablecell>As above.</tablecell><tablecell>IM, PO.</tablecell><tablecell>Not available.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Ketoprofen</target></link></tablecell><tablecell>Comes in free acid, lysine salt, sodium salt and hydrochloride salt forms; the dex-enantiomer comes in<space/><link><target>trometamol</target></link><space/>salt form. Practically insoluble in water; freely soluble in most other solvents. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal, topical, transdermal, intravenous, intramuscular.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Coaccioli S<space/></arg><arg name="title"><space/>Ketoprofen 2.5% gel: a clinical overview.<space/></arg><arg name="journal"><space/>European Review for Medical and Pharmacological Sciences<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>943–9<space/></arg><arg name="date"><space/>August 2011<space/></arg><arg name="pmid"><space/>21845805<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Adachi H, Ioppolo F, Paoloni M, Santilli V<space/></arg><arg name="title"><space/>Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation<space/></arg><arg name="journal"><space/>European Review for Medical and Pharmacological Sciences<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>823–30<space/></arg><arg name="date"><space/>July 2011<space/></arg><arg name="pmid"><space/>21780552<space/></arg><arg name="last2"><space/>Ioppolo<space/></arg><arg name="last3"><space/>Paoloni<space/></arg><arg name="last4"><space/>Santilli<space/></arg></template></extension></tablecell><tablecell>Bioavailability &gt; 92% (oral), 7090% (rectal); protein binding &gt; 99%; volume of distribution = 0.10.2 L/kg; hepatic metabolism; half-life = 1.52 hours (oral), 2.2 hours (rectal), 2 hours (intravenous).<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Kokki<space/></arg><arg name="first1">H<space/></arg><arg name="title"><space/>Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.<space/></arg><arg name="journal"><space/>Paediatric drugs<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>313–29<space/></arg><arg name="date"><space/>October 2010<space/></arg><arg name="pmid"><space/>20799760<space/></arg><arg name="doi"><space/>10.2165/11534910-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Shohin<space/></arg><arg name="first1">IE<space/></arg><arg name="last2">Kulinich<space/></arg><arg name="first2">JI<space/></arg><arg name="last3">Ramenskaya<space/></arg><arg name="first3">GV<space/></arg><arg name="last4">Abrahamsson<space/></arg><arg name="first4">B<space/></arg><arg name="last5">Kopp<space/></arg><arg name="first5">S<space/></arg><arg name="last6">Langguth<space/></arg><arg name="first6">P<space/></arg><arg name="last7">Polli<space/></arg><arg name="first7">JE<space/></arg><arg name="last8">Shah<space/></arg><arg name="first8">VP<space/></arg><arg name="last9">Groot<space/></arg><arg name="first9">DW<space/></arg><arg name="last10">Barends<space/></arg><arg name="first10">Dirk M.<space/></arg><arg name="last11">Dressman<space/></arg><arg name="first11">Jennifer B.<space/></arg><arg name="title"><space/>Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen<space/></arg><arg name="journal"><space/>Journal of Pharmaceutical Sciences<space/></arg><arg name="volume"><space/>101<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>3593–603<space/></arg><arg name="date"><space/>October 2012<space/></arg><arg name="pmid"><space/>22786667<space/></arg><arg name="doi"><space/>10.1002/jps.23233<space/></arg><arg name="url"><space/>http://onlinelibrary.wiley.com/doi/10.1002/jps.23233/pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="display-authors">8<space/></arg></template></extension></tablecell><tablecell><link><target>Rheumatoid arthritis</target></link>,<space/><link><target>osteoarthritis</target></link><space/>and superficial sporting injuries (topical use).<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Sarzi-Puttini<space/></arg><arg name="first1">P<space/></arg><arg name="last2">Atzeni<space/></arg><arg name="first2">F<space/></arg><arg name="last3">Lanata<space/></arg><arg name="first3">L<space/></arg><arg name="last4">Bagnasco<space/></arg><arg name="first4">M<space/></arg><arg name="last5">Colombo<space/></arg><arg name="first5">M<space/></arg><arg name="last6">Fischer<space/></arg><arg name="first6">F<space/></arg><arg name="last7">D'Imporzano<space/></arg><arg name="first7">M<space/></arg><arg name="title"><space/>Pain and ketoprofen: what is its role in clinical practice?<space/></arg><arg name="journal"><space/>Reumatismo<space/></arg><arg name="volume"><space/>62<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>172–88<space/></arg><arg name="date"><space/>July–September 2010<space/></arg><arg name="pmid"><space/>21052564<space/></arg><arg name="doi"><space/>10.4081/reumatismo.2010.172<space/></arg><arg name="url"><space/>http://www.reumatismo.org/index.php/reuma/article/download/reumatismo.2010.172/468<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Ketorolac</target></link></tablecell><tablecell>Comes in the<space/><link><target>trometamol</target></link><space/>salt form; highly soluble in water. Degrades in the presence of light. Acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IM, IV, intranasal, tromethamine and ophthalmologic.</tablecell><tablecell>Bioavailability of IM formulation = 100%; protein binding = 99%; hepatic metabolism mostly via glucoronic acid conjugation and p-hydroxylation; half-life = 56 hours; excretion = urine (91.4%), faeces (6.1%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">NAME OF THE MEDICINE TORADOL® (ketorolac trometamol)</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">ROCHE PRODUCTS PTY LIMITED</arg><arg name="date">3 February 2012</arg><arg name="accessdate">7 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell>Mild-moderate postoperative pain; acute migraine; inflammation of the eye due to cataract surgery or allergic seasonal<space/><link><target>conjunctivitis</target></link>; prevention of acute pseudophakic cystoid macular oedema.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McCormack PL<space/></arg><arg name="title"><space/>Ketorolac 0.45% ophthalmic solution.<space/></arg><arg name="journal"><space/>Drugs & Aging<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>583–9<space/></arg><arg name="date"><space/>July 2011<space/></arg><arg name="pmid"><space/>21721602<space/></arg><arg name="doi"><space/>10.2165/11207450-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sinha VR, Kumar RV, Singh G<space/></arg><arg name="title"><space/>Ketorolac tromethamine formulations: an overview<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Delivery<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>961–75<space/></arg><arg name="date"><space/>September 2009<space/></arg><arg name="pmid"><space/>19663721<space/></arg><arg name="doi"><space/>10.1517/17425240903116006<space/></arg><arg name="last2"><space/>Kumar<space/></arg><arg name="last3"><space/>Singh<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>De Oliveira GS, Agarwal D, Benzon HT<space/></arg><arg name="title"><space/>Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials<space/></arg><arg name="journal"><space/>Anesthesia and Analgesia<space/></arg><arg name="volume"><space/>114<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>424–33<space/></arg><arg name="date"><space/>February 2012<space/></arg><arg name="pmid"><space/>21965355<space/></arg><arg name="doi"><space/>10.1213/ANE.0b013e3182334d68<space/></arg><arg name="last2"><space/>Agarwal<space/></arg><arg name="last3"><space/>Benzon<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Garnock-Jones KP<space/></arg><arg name="title"><space/>Intranasal ketorolac: for short-term pain management.<space/></arg><arg name="journal"><space/>Clinical Drug Investigation<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>361–71<space/></arg><arg name="date"><space/>June 2012<space/></arg><arg name="pmid"><space/>22574632<space/></arg><arg name="doi"><space/>10.2165/11209240-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>He A, Hersh EV<space/></arg><arg name="title"><space/>A review of intranasal ketorolac tromethamine for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level<space/></arg><arg name="journal"><space/>Current Medical Research and Opinion<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1873–80<space/></arg><arg name="date"><space/>December 2012<space/></arg><arg name="pmid"><space/>23098098<space/></arg><arg name="doi"><space/>10.1185/03007995.2012.744302<space/></arg><arg name="last2"><space/>Hersh<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH<space/></arg><arg name="title"><space/>Ketorolac in the treatment of acute migraine: a systematic review<space/></arg><arg name="journal"><space/>Headache<space/></arg><arg name="volume"><space/>53<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>277–87<space/></arg><arg name="date"><space/>February 2013<space/></arg><arg name="pmid"><space/>23298250<space/></arg><arg name="doi"><space/>10.1111/head.12009<space/></arg><arg name="last2"><space/>Doran<space/></arg><arg name="last3"><space/>Kokotillo<space/></arg><arg name="last4"><space/>Campbell<space/></arg><arg name="last5"><space/>Villa-Roel<space/></arg><arg name="last6"><space/>Rowe<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Yilmaz T, Cordero-Coma M, Gallagher MJ<space/></arg><arg name="title"><space/>Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review<space/></arg><arg name="journal"><space/>Eye<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>252–8<space/></arg><arg name="date"><space/>February 2012<space/></arg><arg name="pmid"><space/>22094296<space/></arg><arg name="pmc"><space/>3272202<space/></arg><arg name="doi"><space/>10.1038/eye.2011.296<space/></arg><arg name="url"><space/>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272202/pdf/eye2011296a.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="last2"><space/>Cordero-Coma<space/></arg><arg name="last3"><space/>Gallagher<space/></arg></template></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Lornoxicam</target></link></tablecell><tablecell>Hydrochloride salt form used; oxicam derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 99%; volume of distribution = 0.2 L/kg; half-life = 35 hours; excretion = faeces (51%), urine (42%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Balfour JA, Fitton A, Barradell LB<space/></arg><arg name="title"><space/>Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>51<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>639–57<space/></arg><arg name="date"><space/>April 1996<space/></arg><arg name="pmid"><space/>8706598<space/></arg><arg name="doi"><space/>10.2165/00003495-199651040-00008<space/></arg><arg name="last2"><space/>Fitton<space/></arg><arg name="last3"><space/>Barradell<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Skjodt NM, Davies NM<space/></arg><arg name="title"><space/>Clinical pharmacokinetics of lornoxicam. A short half-life oxicam<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>421–8<space/></arg><arg name="date"><space/>June 1998<space/></arg><arg name="pmid"><space/>9646006<space/></arg><arg name="doi"><space/>10.2165/00003088-199834060-00001<space/></arg><arg name="last2"><space/>Davies<space/></arg></template></extension></tablecell><tablecell>Acute and chronic pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Loxoprofen</target></link></tablecell><tablecell>Comes in sodium salt form. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A</tablecell><tablecell>Local inflammation and pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Magnesium salicylate</target></link></tablecell><tablecell>Comes in free form; soluble in water and ethanol; salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Meclofenamic acid</target></link></tablecell><tablecell>Comes in free acid and sodium salt form, sodium salt is the form used in human medicine; practically insoluble in water (free acid) and freely soluble in water (sodium salt); sensitive to degradation by air and light.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 99%; half-life = 24 hours; hepatically metabolised via oxidation, hydroxylation, dehalogenation and conjugation with glucuronic acid; excretion = urine, faeces (2030%).<extension extension_name='ref' name="MD"></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis; mild-moderate pain; dysmenorrhoea;<space/><link><target>menorrhagia</target></link>.</tablecell><tablecell>As per other systemic NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Mefenamic acid</target></link></tablecell><tablecell>Comes in free acid form; practically insoluble in water, fairly insoluble in organic solvents; degrades on contact with air and light. Anthranilic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding extensive; hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link>; half-life = 2 hours; excretion = urine (66%), faeces (2025%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">PRODUCT INFORMATION PONSTAN® CAPSULES (mefenamic acid)</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Pfizer Australia Pty Ltd</arg><arg name="date">12 October 2012</arg><arg name="accessdate">7 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell>Inflammatory pain and heavy menstrual bleeding.<extension extension_name='ref' name="AMH"></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Mofezolac</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal and joint pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Morniflumate</target></link></tablecell><tablecell>Comes in free acid form; niflumic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>Not available.</tablecell><tablecell>Inflammatory conditions.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Nabumetone</target></link></tablecell><tablecell>Comes in free acid form; practically insoluble in water, freely soluble in acetone; degrades on contact with air and light.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 99%; hepatically metabolised; half-life = 24 hours; excretion = urine (80%), faeces (9%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Relafen (nabumetone) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://reference.medscape.com/drug/relafen-nabumetone-343295#showall</arg></template></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Naproxen</target></link></tablecell><tablecell>Comes in free acid and sodium form; practically insoluble in water in free form, freely soluble in water (sodium salt), fairly soluble in most organic solvents. Degrades on contact with air and light. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = ?; protein binding &gt; 99.5%; volume of distribution = 10% of bodyweight; half-life = 1215 hours; excretion = urine (95%), faeces (&lt;3%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Todd PA, Clissold SP<space/></arg><arg name="title"><space/>Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>40<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>91–137<space/></arg><arg name="date"><space/>July 1990<space/></arg><arg name="pmid"><space/>2202585<space/></arg><arg name="doi"><space/>10.2165/00003495-199040010-00006<space/></arg><arg name="last2"><space/>Clissold<space/></arg></template></extension></tablecell><tablecell>Rheumatoid arthritis; osteoarthritis; ankylosing spondylitis;<space/><link><target>juvenile idiopathic arthritis</target></link>; inflammatory pain; heavy menstrual bleeding.</tablecell><tablecell>As above; less prone to causing thrombotic events compared to other non-selective NSAIDs.<extension extension_name='ref' name="card"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Nepafenac</target></link></tablecell><tablecell>Comes in free form; related to amfenac.</tablecell><tablecell>As above.</tablecell><tablecell>Ophthalmologic.</tablecell><tablecell>Unavailable.</tablecell><tablecell>Inflammation and pain following cataract surgery.</tablecell><tablecell>As per other ophthalmologic NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Niflumic acid</target></link></tablecell><tablecell>Comes in free acid form, glycinamide and ethyl ester form; practically insoluble in water, soluble in ethanol, acetone and methanol. Nicotinic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal (ethyl ester,<space/><link><target>morniflumate</target></link>).</tablecell><tablecell>Unavailable.</tablecell><tablecell>Musculoskeletal, joint and mouth inflammatory disorders.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Oxaprozin</target></link></tablecell><tablecell>Comes in potassium and free acid forms; degrades upon contact with light. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = ?; protein binding &gt; 99.5%; volume of distribution = 0.150.25 L/kg; half-life = 5060 hours; excretion = urine (65), faeces (35%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Daypro (oxaprozin) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://reference.medscape.com/drug/daypro-oxaprozin-343297#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Todd PA, Brogden RN<space/></arg><arg name="title"><space/>Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>291–312<space/></arg><arg name="date"><space/>October 1986<space/></arg><arg name="pmid"><space/>3536423<space/></arg><arg name="doi"><space/>10.2165/00003495-198632040-00001<space/></arg><arg name="last2"><space/>Brogden<space/></arg></template></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Oxyphenbutazone</target></link></tablecell><tablecell>Comes in free form. Phenylbutazone.</tablecell><tablecell>As above.</tablecell><tablecell>PO, Ophthalmologic.</tablecell><tablecell>Unavailable.</tablecell><tablecell>Ophthalmologic:<space/><link><target>Episcleritis</target></link>. Systemic (now seldom used due to adverse effects): ankylosing spondylitis; rheumatoid arthritis; osteoarthritis.</tablecell><tablecell>As per other ophthalmologic NSAIDs. For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc.</tablecell></tablerow><tablerow><tablecell><link><target>Phenazone</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>PO,<space/><link><target>otolaryngologic</target></link>.</tablecell><tablecell>Protein binding &lt; 10%; half-life = 12 hours; hepatic metabolised; excretion = urine (primary), faeces.</tablecell><tablecell>Acute<space/><link><target>otitis media</target></link>.</tablecell><tablecell>Nephrotoxicity and haematologic toxicity and other AEs typical of NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Phenylbutazone</target></link></tablecell><tablecell>Comes in free form; practically insoluble in water, freely soluble in most organic solvents; degrades upon contact with light and air.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal, topical.</tablecell><tablecell>No data available.</tablecell><tablecell>Ankylosing spondylitis; acute gout; osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>Haematologic toxicity (including agranulocytosis, aplastic anaemia) and AEs typical of NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Piketoprofen</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As above.</tablecell><tablecell>Topical.</tablecell><tablecell>N/A.</tablecell><tablecell>Musculoskeletal, joint, peri-articular and soft-tissue disorders.</tablecell><tablecell>As per other topical NSAIDs.</tablecell></tablerow><tablerow><tablecell><link><target>Piroxicam</target></link></tablecell><tablecell>Comes in free acid and betadex salt forms; practically insoluble in water, slightly soluble in ethanol; degrades on contact with air and light. Enolic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, topical.</tablecell><tablecell>Protein binding = 99%; extensively hepatically metabolised; half-life = 3645 hours; excretion = urine, faeces.<extension extension_name='ref'><template><target>cite web</target><arg name="title">CHEMMART PIROXICAM CAPSULES</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Apotex Pty Ltd</arg><arg name="accessdate">7 April 2014</arg><arg name="date">18 December 2013</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brogden RN, Heel RC, Speight TM, Avery GS<space/></arg><arg name="title"><space/>Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>292–323<space/></arg><arg name="date"><space/>October 1984<space/></arg><arg name="pmid"><space/>6386426<space/></arg><arg name="doi"><space/>10.2165/00003495-199448060-00007<space/></arg><arg name="last2"><space/>Heel<space/></arg><arg name="last3"><space/>Speight<space/></arg><arg name="last4"><space/>Avery<space/></arg></template></extension></tablecell><tablecell>Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and sports injuries (topical use).<extension extension_name='ref' name="AMH"></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Proglumetacin</target></link></tablecell><tablecell>Comes in maleate salt form; indometacin derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal, topical.</tablecell><tablecell>Not available.</tablecell><tablecell>Musculoskeletal and joint disorders.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Proquazone</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>Not available.</tablecell><tablecell>As above.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Pranoprofen</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>PO, ophthalmologic.</tablecell><tablecell>Not available.</tablecell><tablecell>Pain, inflammation and fever.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Salamidacetic acid</target></link></tablecell><tablecell>Comes in sodium and diethylamine salt forms; salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Unavailable.</tablecell><tablecell>Musculoskeletal disorders.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Salicylamide</target></link></tablecell><tablecell>Fairly insoluble in water and chloroform; soluble in most other organic solvents; salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO, topical.</tablecell><tablecell>No data.</tablecell><tablecell>Muscular and rheumatic diseases.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Salol</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>PO, topical.</tablecell><tablecell>No data.</tablecell><tablecell>Lower urinary tract infections.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Salsalate</target></link></tablecell><tablecell>Degrades upon contact with air; salicylate derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Hepatic metabolism; half-life = 78 hours; excretion = urine.<extension extension_name='ref'><template><target>cite web</target><arg name="title">(salsalate) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">7 April 2014</arg><arg name="url">http://reference.medscape.com/drug/salsalate-343340#showall</arg></template></extension></tablecell><tablecell>Rheumatoid arthritis, osteoarthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Sodium salicylate</target></link></tablecell><tablecell>Freely soluble in water; degrades upon contact with air and light; salicylate.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IV, topical.</tablecell><tablecell>No data.</tablecell><tablecell>Pain, fever and rheumatic conditions.</tablecell><tablecell>Cardiac problems; otherwise as above.</tablecell></tablerow><tablerow><tablecell><link><target>Sulindac</target></link></tablecell><tablecell>Comes in free acid and sodium salt forms; practically insoluble in water and hexane, very slightly soluble in most organic solvents. Degrades upon contact with light. Acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>Bioavailability = 90%; protein binding = 93% (sulindac), 98% (active metabolite); hepatic metabolism; excretion = urine (50%), faeces (25%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Aclin Sulindac</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Alphapharm Pty Limited</arg><arg name="date">8 November 2011</arg><arg name="accessdate">7 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell>Rheumatoid arthritis; osteoarthritis; gout; ankylosing spondylitis; inflammatory pain.<extension extension_name='ref' name="AMH"></extension></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Suxibuzone</target></link></tablecell><tablecell>Practically insoluble in water, soluble in ethanol and acetone; phenylbutazone.</tablecell><tablecell>As above.</tablecell><tablecell>PO, topical.</tablecell><tablecell>No data.</tablecell><tablecell>Musculoskeletal and joint disorders.</tablecell><tablecell>As per phenylbutazone.</tablecell></tablerow><tablerow><tablecell><link><target>Tenoxicam</target></link></tablecell><tablecell>Comes as free acid; practically insoluble in water, fairly insoluble in organic solvents; degrades upon contact with light.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>Bioavailability = 100% (oral), 80% (rectal); protein binding = 99%; volume of distribution = 0.15 L/kg; half-life = 6075 hours; excretion = urine (67%), faeces (33%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gonzalez JP, Todd PA<space/></arg><arg name="title"><space/>Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>289–310<space/></arg><arg name="date"><space/>September 1987<space/></arg><arg name="pmid"><space/>3315620<space/></arg><arg name="doi"><space/>10.2165/00003495-198734030-00001<space/></arg><arg name="last2"><space/>Todd<space/></arg></template></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis; soft tissue injury.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tetridamine</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>Vaginal.</tablecell><tablecell>No data.</tablecell><tablecell><link><target>Vaginitis</target></link>.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tiaprofenic acid</target></link></tablecell><tablecell>Comes as free acid; practically insoluble in water but freely soluble in most organic solvents; propionic acid derivative; degrades upon contact with light. Propionic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 99%; volume of distribution = 0.10.2 L/kg; hepatic metabolism; half-life = 24 hours.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Davies NM<space/></arg><arg name="title"><space/>Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.<space/></arg><arg name="journal"><space/>Clinical pharmacokinetics<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>331–47<space/></arg><arg name="date"><space/>November 1996<space/></arg><arg name="pmid"><space/>9118583<space/></arg><arg name="doi"><space/>10.2165/00003088-199631050-00002<space/></arg></template></extension></tablecell><tablecell>Ankylosing spondylitis; osteoarthritis; rheumatoid arthritis; fibrosis; capsulitis; soft-tissue disorders.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tiaramide</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Pain; inflammation.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tinoridine</target></link></tablecell><tablecell>No data.</tablecell><tablecell>As above.</tablecell><tablecell>No data.</tablecell><tablecell>No data.</tablecell><tablecell>Pain; inflammation.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tolfenamic acid</target></link></tablecell><tablecell>Comes as free acid; practically insoluble in water; degrades upon contact with light; anthranilic acid.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 99%; half-life = 2 hours; hepatically metabolised; excretion = urine (90%), faeces.</tablecell><tablecell>Migraine; osteoarthritis; rheumatoid arthritis; dysmenorrhoea.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Tolmetin</target></link></tablecell><tablecell>Comes in sodium salt form; freely soluble in water, slightly soluble in ethanol, freely soluble in methanol. Acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 99%; volume of distribution = 710 L; half-life = 1 hour; excretion = urine (90%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brogden RN, Heel RC, Speight TM, Avery GS<space/></arg><arg name="title"><space/>Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>429–50<space/></arg><arg name="date"><space/>June 1978<space/></arg><arg name="pmid"><space/>350558<space/></arg><arg name="doi"><space/>10.2165/00003495-197815060-00002<space/></arg><arg name="last2"><space/>Heel<space/></arg><arg name="last3"><space/>Speight<space/></arg><arg name="last4"><space/>Avery<space/></arg></template></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Ufenamate</target></link></tablecell><tablecell>No data.</tablecell><tablecell>No data.</tablecell><tablecell>Topical.</tablecell><tablecell>No data.</tablecell><tablecell>Inflammatory skin disorders.</tablecell><tablecell>As per other topical NSAIDs.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>COX-2 selective inhibitors</bold></tablecell></tablerow><tablerow><tablecell><link><target>Celecoxib</target></link></tablecell><tablecell>Comes in free form; practically insoluble in water, fairly soluble in organic solvents. Degrades on contact with light and moisture.<space/><link><target>Sulfonamide</target></link>.</tablecell><tablecell>Selective COX-2 inhibitor.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 97%; hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link>; faeces (57%), urine (27%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McCormack PL<space/></arg><arg name="title"><space/>Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>71<space/></arg><arg name="issue"><space/>18<space/></arg><arg name="pages"><space/>2457–89<space/></arg><arg name="date"><space/>December 2011<space/></arg><arg name="pmid"><space/>22141388<space/></arg><arg name="doi"><space/>10.2165/11208240-000000000-00000<space/></arg></template></extension></tablecell><tablecell>Rheumatoid arthritis; osteoarthritis; ankylosing spondylitis; pain due to dysmenorrhoea or injury.</tablecell><tablecell>As per non-selective NSAIDs. More prone to causing thrombotic events than most of them, however, except diclofenac.</tablecell></tablerow><tablerow><tablecell><link><target>Etodolac</target></link></tablecell><tablecell>Comes in free form; practically insoluble in water, freely soluble in acetone and dehydrated alcohol. Acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = ?; protein binding &gt; 99%; volume of distribution = 0.41 L/kg; half-life = 67 hours; excretion = urine (73%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lynch S, Brogden RN<space/></arg><arg name="title"><space/>Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>288–300<space/></arg><arg name="date"><space/>April 1986<space/></arg><arg name="pmid"><space/>2940079<space/></arg><arg name="doi"><space/>10.2165/00003495-198631040-00002<space/></arg><arg name="last2"><space/>Brogden<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Balfour JA, Buckley MM<space/></arg><arg name="title"><space/>Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>42<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>274–99<space/></arg><arg name="date"><space/>August 1991<space/></arg><arg name="pmid"><space/>1717225<space/></arg><arg name="doi"><space/>10.2165/00003495-199142020-00008<space/></arg><arg name="last2"><space/>Buckley<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brocks DR, Jamali F<space/></arg><arg name="title"><space/>Etodolac clinical pharmacokinetics<space/></arg><arg name="journal"><space/>Clinical pharmacokinetics<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>259–74<space/></arg><arg name="date"><space/>April 1994<space/></arg><arg name="pmid"><space/>8013160<space/></arg><arg name="doi"><space/>10.2165/00003088-199426040-00003<space/></arg><arg name="last2"><space/>Jamali<space/></arg></template></extension></tablecell><tablecell>Rheumatoid arthritis, including juvenile idiopathic arthritis; osteoarthritis; acute pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Etoricoxib</target></link></tablecell><tablecell>Comes in free form;<space/><link><target>sulfonamide</target></link>.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 100%; protein binding = 91.4%; volume of distribution = 120 L; half-life = 22 hours; hepatic metabolism; excretion = urine (70%), faeces (20%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM<space/></arg><arg name="title"><space/>Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>703–20<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18840026<space/></arg><arg name="doi"><space/>10.2165/00003088-200847110-00002<space/></arg><arg name="last2"><space/>Reynolds<space/></arg><arg name="last3"><space/>Remsberg<space/></arg><arg name="last4"><space/>Vega-Villa<space/></arg><arg name="last5"><space/>Davies<space/></arg></template></extension></tablecell><tablecell>Acute pain; gout; osteoarthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Lumiracoxib</target></link></tablecell><tablecell>Comes in free form; acetic acid derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 74%; protein binding &gt; 98%; extensive hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link>; half-life = 36 hours; excretion = Urine (50%), faeces (50%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bannwarth B, Bérenbaum F<space/></arg><arg name="title"><space/>Lumiracoxib in the management of osteoarthritis and acute pain<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1551–64<space/></arg><arg name="date"><space/>July 2007<space/></arg><arg name="pmid"><space/>17661736<space/></arg><arg name="doi"><space/>10.1517/14656566.8.10.1551<space/></arg><arg name="last2"><space/>Bérenbaum<space/></arg></template></extension></tablecell><tablecell>Osteoarthritis.</tablecell><tablecell>As above, plus hepatotoxicity.</tablecell></tablerow><tablerow><tablecell><link><target>Meloxicam</target></link></tablecell><tablecell>Comes in free form; fairly insoluble in water and in most organic solvents; oxicam derivative.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal.</tablecell><tablecell>Bioavailability = 89%; protein binding &gt; 99%; volume of distribution = 0.10.2 L/kg; half-life = 2224 hours; extensive hepatic metabolism; excretion = urine (45%), faeces (47%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Davies NM, Skjodt NM<space/></arg><arg name="title"><space/>Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>115–26<space/></arg><arg name="date"><space/>February 1999<space/></arg><arg name="pmid"><space/>10092958<space/></arg><arg name="doi"><space/>10.2165/00003088-199936020-00003<space/></arg><arg name="last2"><space/>Skjodt<space/></arg></template></extension></tablecell><tablecell>Osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Nimesulide</target></link></tablecell><tablecell>Comes in free and betadex form; practically insoluble in water and ethanol, soluble in acetone.</tablecell><tablecell>As above.</tablecell><tablecell>PO, rectal, topical.</tablecell><tablecell>Unavailable.</tablecell><tablecell>Acute pain; dysmenorrhoea; sprains (topical);<space/><link><target>tendinitis</target></link>.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Parecoxib</target></link></tablecell><tablecell>Comes in sodium salt form; sulfonamide.</tablecell><tablecell>As above.</tablecell><tablecell>IM, IV.</tablecell><tablecell>Plasma binding = 98%; volume of distribution = 55 L; hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link>,<space/><link><target>CYP3A4</target></link>; half-life = 8 hours; excretion = urine (70%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">PRODUCT INFORMATION DYNASTAT parecoxib (as sodium)</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Pfizer Australia Pty Ltd</arg><arg name="date">6 February 2013</arg><arg name="accessdate">7 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell>Postoperative pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Rofecoxib</target></link></tablecell><tablecell>Comes in free form; sulfonamide.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 93%; protein binding = 87%; hepatic metabolism; half-life = 17 hours.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Scott LJ, Lamb HM<space/></arg><arg name="title"><space/>Rofecoxib<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>58<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>499–505; discussion 506–7<space/></arg><arg name="date"><space/>September 1999<space/></arg><arg name="pmid"><space/>10493277<space/></arg><arg name="doi"><space/>10.2165/00003495-199958030-00016<space/></arg><arg name="last2"><space/>Lamb<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hillson JL, Furst DE<space/></arg><arg name="title"><space/>Rofecoxib<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>1053–66<space/></arg><arg name="date"><space/>July 2000<space/></arg><arg name="pmid"><space/>11249495<space/></arg><arg name="doi"><space/>10.1517/14656566.1.5.1053<space/></arg><arg name="last2"><space/>Furst<space/></arg></template></extension></tablecell><tablecell>Acute pain; osteoarthritis; rheumatoid arthritis.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Valdecoxib</target></link></tablecell><tablecell>Comes in free form; sulfonamide.</tablecell><tablecell>As above.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 83%; protein binding = 98%; hepatic metabolism, mostly via<space/><link><target>CYP3A4</target></link><space/>and<space/><link><target>CYP2C9</target></link>; half-life = 8.11 hours; excretion = urine (90%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ormrod D, Wellington K, Wagstaff AJ<space/></arg><arg name="title"><space/>Valdecoxib<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>62<space/></arg><arg name="issue"><space/>14<space/></arg><arg name="pages"><space/>2059–71; discussion 2072–3<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12269850<space/></arg><arg name="doi"><space/>10.2165/00003495-200262140-00005<space/></arg><arg name="last2"><space/>Wellington<space/></arg><arg name="last3"><space/>Wagstaff<space/></arg></template></extension></tablecell><tablecell>Pain from<space/><link><target>dysmenorrhoea</target></link>; rheumatoid arthritis; osteoarthritis.</tablecell><tablecell>As above and also potentially fatal skin reactions (e.g.<space/><link><target>toxic epidermal necrolysis</target></link>).</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold><xhtml:big><link><target>Opioids</target></link></xhtml:big></bold></tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Those with a morphine skeleton</bold></tablecell></tablerow><tablerow><tablecell><link><target>Buprenorphine</target></link></tablecell><tablecell>Comes in free and hydrochloride salt forms; fairly insoluble in water, soluble in ethanol, methanol and acetone; degrades upon contact with light.</tablecell><tablecell>Partial agonist at the mu opioid receptor; agonist at delta opioid receptor; antagonist at kappa opioid receptor.</tablecell><tablecell>Sublingual, transdermal, IM, IV, intranasal, epidural, SC.</tablecell><tablecell>Bioavailability = 79% (sublingual); protein binding = 96%: volume of distribution = 97187 L/kg; half-life = 2036 hours; excretion = urine, faeces.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Buprenex, Subutex (buprenorphine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/subutex-buprenorphine-343326#showall</arg></template></extension></tablecell><tablecell>Opioid dependence, moderate-severe pain.</tablecell><tablecell>As per other opioids, respiratory effects are subject to a ceiling effect.</tablecell></tablerow><tablerow><tablecell><link><target>Codeine</target></link></tablecell><tablecell>Comes in free form, hydrochloride salt, sulfate salt and phosphate salts; soluble in boiling water (free form), freely soluble in ethanol (free form), soluble/freely soluble in water (salt forms); sensitive to degradation by light. Methoxy analogue of morphine.</tablecell><tablecell>Metabolised to morphine, which activates the<space/><link><target>opioid receptors</target></link>.</tablecell><tablecell>PO, IM, IV.</tablecell><tablecell>Extensive hepatic metabolism, mostly via<space/><link><target>CYP2D6</target></link>, to<space/><link><target>morphine</target></link>; half-life = 34 hours; excretion = urine (86%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">PRODUCT INFORMATION ACTACODE</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Aspen Pharma Pty Ltd</arg><arg name="date">19 September 2006</arg><arg name="accessdate">8 April 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension></tablecell><tablecell>Mild-moderate pain, often in combination with<space/><link><target>paracetamol</target></link><space/>or<space/><link><target>ibuprofen</target></link>.</tablecell><tablecell>Constipation, dependence, sedation, itching, nausea, vomiting and respiratory depression.</tablecell></tablerow><tablerow><tablecell><link><target>Diamorphine</target></link></tablecell><tablecell>Comes in hydrochloride salt form; freely soluble in water, soluble in alcohol; degrades upon contact with light. Diacetyl derivative of morphine.</tablecell><tablecell>Rapidly hydrolysed to 6-acetylmorphine and then to morphine after crossing the blood-brain barrier which in turn activates the opioid receptors in the CNS.</tablecell><tablecell>IM, intrathecal, intranasal, PO, IV, SC.</tablecell><tablecell>Extensively metabolised to morphine with 6-acetylmorphine as a possible intermediate. Mostly excreted in urine.</tablecell><tablecell>Severe pain (including labour pain); cough due to terminal lung cancer; angina; left ventricular failure.</tablecell><tablecell>As above. Higher potential for abuse compared to other opioids due to its rapid penetration of the blood-brain barrier.</tablecell></tablerow><tablerow><tablecell><link><target>Dihydrocodeine</target></link></tablecell><tablecell>Comes in freebase, hydrochloride, phosphate, polistirex, thiocyanate, tartrate, bitartrate and hydrogen tartrate salt forms; freely soluble in water, practically insoluble in organic solvents (hydrogen tartrate salt); degrades upon contact with air and light.</tablecell><tablecell>Opioid receptor agonist.</tablecell><tablecell>IM, IV, PO, SC.</tablecell><tablecell>Bioavailability = 20%; extensive hepatic metabolism, partly via<space/><link><target>CYP2D6</target></link><space/>to<space/><link><target>dihydromorphine</target></link><space/>and<space/><link><target>CYP3A4</target></link><space/>to<space/><link><target>nordihydrocodeine</target></link>; half-life = 3.5 5 hours; excretion = urine.</tablecell><tablecell>Moderate-severe pain; usually in combination with paracetamol and/or aspirin.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Ethylmorphine</target></link></tablecell><tablecell>Comes in freebase, hydrochloride, camphorate and camsilate salt forms; soluble in water and alcohol; degrades upon contact with light.</tablecell><tablecell>Opioid receptor ligand.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Cough suppressant.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Hydrocodone</target></link></tablecell><tablecell>Comes in hydrochloride/tartrate salt form; freely soluble in water, practically insoluble in most organic solvents; degrades upon contact with light/air.</tablecell><tablecell>Opioid receptor ligand.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 19%; extensively hepatically metabolised, mostly via<space/><link><target>CYP3A4</target></link>, but via<space/><link><target>CYP2D6</target></link><space/>to a lesser extent to<space/><link><target>hydromorphone</target></link>; half-life = 8 hours; excretion = urine.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Zohydro ER (hydrocodone) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/zohydro-er-hydrocodone-343312#showall</arg></template></extension></tablecell><tablecell>Chronic pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Hydromorphone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; freely soluble in water, fairly insoluble in organic solvents; degrades upon contact with light or temperatures outside 15&amp;nbsp;C and 35&amp;nbsp;C.</tablecell><tablecell>Opioid receptor agonist.</tablecell><tablecell>IM, IV, PO, SC.</tablecell><tablecell>Bioavailability = 5062% (oral); protein binding = 819%; extensively hepatically metabolised; half-life = 23 hours; excretion = urine.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Dilaudid, Dilaudid HP (hydromorphone) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/dilaudid-hydromorphone-343313#showall</arg></template></extension></tablecell><tablecell>Moderate-severe pain; cough.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Morphine</target></link></tablecell><tablecell>Comes in freebase form, hydrochloride salt, sulfate salt and tartrate salt forms; soluble in water; degrades in the presence of light.</tablecell><tablecell>Opioid receptor agonist (, , ).</tablecell><tablecell>IM, intrathecal, PO, IV, SC, rectal.</tablecell><tablecell>Protein binding = 35%; extensive hepatic metabolism, with some metabolism occur in the gut after oral administration; half-life = 2 hours; excretion = urine (90%).</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Nicomorphine</target></link></tablecell><tablecell>Di<link><target>nicotinic acid</target></link><space/>ester derivative of morphine.</tablecell><tablecell>As above.</tablecell><tablecell>IM, IV, PO, rectal, SC.</tablecell><tablecell>No available data.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Oxycodone</target></link></tablecell><tablecell>Comes in freebase, hydrochloride and<space/><link><target>terephthalate</target></link><space/>salt forms; freely soluble in water and practically insoluble in organic solvents; degrades upon contact with air.</tablecell><tablecell>Opioid receptor agonist.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 6087%; protein binding = 45%; volume of distribution = 2.6 L/kg; extensively metabolised in the liver via<space/><link><target>CYP3A4</target></link><space/>and to a lesser extent via<space/><link><target>CYP2D6</target></link><space/>to<space/><link><target>oxymorphone</target></link>; half-life = 24 hours; excretion = urine (83%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Roxicodone, OxyContin (oxycodone) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/roxicodone-oxycontin-oxycodone-343321#showall</arg></template></extension></tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Oxymorphone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; fairly soluble in water (1 in 4), practically insoluble in most organic solvents; degrades upon contact with air, light and temperatures outside 15&amp;nbsp;C to 30&amp;nbsp;C.</tablecell><tablecell>As above.</tablecell><tablecell>PO, IM, SC.</tablecell><tablecell>Bioavailability = 10% (oral); protein binding = 1012%; volume of distribution = 1.944.22 L/kg; hepatic metabolism; half-life = 79 hours, 911 hours (XR); excretion = urine, faeces.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Opana, Opana ER (oxymorphone) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/opana-er-oxymorphone-343322#showall</arg></template></extension></tablecell><tablecell>Postoperative analgesia/anaesthesia; moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Morphinans</bold></tablecell></tablerow><tablerow><tablecell><link><target>Butorphanol</target></link></tablecell><tablecell>Comes in tartrate salt form; sparingly soluble in water, insoluble in most organic solvents; degrades upon contact with air and at temperatures outside the range of 15&amp;nbsp;C and 30&amp;nbsp;C.</tablecell><tablecell>Kappa opioid receptor agonist; mu opioid receptor partial agonist.</tablecell><tablecell>IM, IV, intranasal.</tablecell><tablecell>Bioavailability = 6070% (intranasal); protein binding = 80%; volume of distribution = 487 L; hepatic metabolism, mostly via hydroxylation; excretion = urine (mostly); half-life = 4.6 hours.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Stadol (butorphanol) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate"><space/>8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/butorphanol-343327#showall</arg></template></extension></tablecell><tablecell>Moderate-severe pain, including labour pain.</tablecell><tablecell>As above, but with a higher propensity for causing hallucinations and delusions. Respiratory depression is subject to ceiling effect.</tablecell></tablerow><tablerow><tablecell><link><target>Levorphanol</target></link></tablecell><tablecell>Comes in tartrate salt form; fairly insoluble in water (1 in 50) and fairly insoluble in ethanol, chloroform and ether; unstable outside of 15&amp;nbsp;C and 30&amp;nbsp;C; phenanthrene derivative.</tablecell><tablecell>Mu opioid; NMDA antagonist;<space/><link><target>serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link>.<extension extension_name='ref' name="supp07"><template><target>cite journal</target><arg name="author"><space/>Prommer E<space/></arg><arg name="title"><space/>Levorphanol: the forgotten opioid.<space/></arg><arg name="journal"><space/>Supportive Care in Cancer<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>259–64<space/></arg><arg name="date"><space/>March 2007<space/></arg><arg name="pmid"><space/>17039381<space/></arg><arg name="doi"><space/>10.1007/s00520-006-0146-2<space/></arg></template></extension></tablecell><tablecell>PO, IM, IV, SC.</tablecell><tablecell>Protein binding = 40%; extensive first-pass metabolism; half-life = 1216 hours, 30 hours (repeated dosing).<extension extension_name='ref' name="supp07"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">Levo Dromoran (levorphanol) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/levorphanol-343314#showall</arg></template></extension></tablecell><tablecell>Acute/chronic pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Nalbuphine</target></link></tablecell><tablecell>Comes primarily as its hydrochloride salt.</tablecell><tablecell>Full agonist at<space/><link><target>kappa opioid receptor</target><trail>s</trail></link>, partial agonist/antagonist at the<space/><link><target>mu opioid receptors</target></link>.<extension extension_name='ref' name="MD"></extension></tablecell><tablecell>IM, IV, SC.</tablecell><tablecell>Protein binding = not significant; hepatic metabolism; half-life = 5 hours; excretion = urine, faeces.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Nubain (nalbuphine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/nalbuphine-343329#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Errick JK, Heel RC<space/></arg><arg name="title"><space/>Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>191–211<space/></arg><arg name="date"><space/>September 1983<space/></arg><arg name="pmid"><space/>6137354<space/></arg><arg name="doi"><space/>10.2165/00003495-198326030-00002<space/></arg><arg name="last2"><space/>Heel<space/></arg></template></extension></tablecell><tablecell>Pain; anaesthesia supplement; opioid-induced pruritus.</tablecell><tablecell>As above. Respiratory depression is subject to ceiling effect.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Benzomorphans</bold></tablecell></tablerow><tablerow><tablecell><link><target>Dezocine</target></link></tablecell><tablecell>No data available.</tablecell><tablecell>Mixed opioid agonist-antagonist.</tablecell><tablecell>IM, IV.</tablecell><tablecell>Volume of distribution = 912 L/kg; half-life = 2.22.7 hours.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Eptazocine</target></link></tablecell><tablecell>Comes as hydrobromide salt.</tablecell><tablecell>As above.</tablecell><tablecell>IM, SC.</tablecell><tablecell>No data.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Pentazocine</target></link></tablecell><tablecell>Comes in free, hydrochloride and lactate salt forms; fairly insoluble in water (1:30 or less), more soluble in ethanol and chloroform; degrades upon contact with air and light.</tablecell><tablecell>Kappa opioid receptor agonist; mu opioid receptor antagonist/partial agonist.</tablecell><tablecell>IM, IV, SC.</tablecell><tablecell>Bioavailability = 6070%; protein binding = 60%; hepatic metabolism; half-life = 23 hours; excretion = urine (primary), faeces.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brogden RN, Speight TM, Avery GS<space/></arg><arg name="title"><space/>Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>6–91<space/></arg><arg name="year"><space/>1973<space/></arg><arg name="pmid"><space/>4578369<space/></arg><arg name="doi"><space/>10.2165/00003495-197305010-00002<space/></arg><arg name="last2"><space/>Speight<space/></arg><arg name="last3"><space/>Avery<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">Talwin (pentazocine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/talwin-pentazocine-343330#showall</arg></template></extension></tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As above. Respiratory effects are subject to a ceiling effect.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Phenylpiperidines</bold></tablecell></tablerow><tablerow><tablecell><link><target>Anileridine</target></link></tablecell><tablecell>Comes in free, hydrochloride and phosphate forms; fairly insoluble in water, soluble in ethanol, ether and chloroform; degrades upon contact with air and light.</tablecell><tablecell>Mu opioid receptor agonist.</tablecell><tablecell>IM, IV.</tablecell><tablecell>No data.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids.</tablecell></tablerow><tablerow><tablecell><link><target>Ketobemidone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; freely soluble in water, soluble in ethanol and fairly insoluble in<space/><link><target>dichloromethane</target></link>.</tablecell><tablecell>Mu opioid; NMDA antagonist.</tablecell><tablecell>PO, IM, IV, rectal.</tablecell><tablecell>Bioavailability = 34% (oral), 44% (rectal); half-life = 23.5 hours.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Anderson P, Arnér S, Bondesson U, Boréus LO, Hartvig P<space/></arg><arg name="title"><space/>Single-dose kinetics and bioavailability of ketobemidone<space/></arg><arg name="journal"><space/>Acta Anaesthesiologica Scandinavica. Supplementum<space/></arg><arg name="volume"><space/>74<space/></arg><arg name="pages"><space/>59–62<space/></arg><arg name="year"><space/>1982<space/></arg><arg name="pmid"><space/>6124079<space/></arg><arg name="last2"><space/>Arnér<space/></arg><arg name="last3"><space/>Bondesson<space/></arg><arg name="last4"><space/>Boréus<space/></arg><arg name="last5"><space/>Hartvig<space/></arg></template></extension></tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids.</tablecell></tablerow><tablerow><tablecell><link><target>Pethidine</target></link></tablecell><tablecell>Comes in hydrochloride form; very soluble in water, sparingly soluble in ether, soluble in ethanol; degrades upon contact with air and light.</tablecell><tablecell>Mu opioid receptor agonist with some serotonergic effects.</tablecell><tablecell>IM, IV, PO, SC.</tablecell><tablecell>Bioavailability = 5060%; protein binding = 6575%; hepatic metabolism; half-life = 2.54 hours; excretion = urine (primarily).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Demerol, Pethidine (meperidine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/demerol-meperidine-343315#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Shipton E<space/></arg><arg name="title">Should New Zealand continue signing up to the Pethidine Protocol?<space/></arg><arg name="journal">The New Zealand Medical Journal<space/></arg><arg name="volume">119<space/></arg><arg name="issue">1230<space/></arg><arg name="pages">U1875<space/></arg><arg name="date">March 2006<space/></arg><arg name="pmid">16532042<space/></arg><arg name="url">http://journal.nzma.org.nz/journal/119-1230/1875/content.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20140408211938/http://journal.nzma.org.nz/journal/119-1230/1875/content.pdf<space/></arg><arg name="archivedate">April 8, 2014<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Latta KS, Ginsberg B, Barkin RL<space/></arg><arg name="title"><space/>Meperidine: a critical review<space/></arg><arg name="journal"><space/>American Journal of Therapeutics<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>53–68<space/></arg><arg name="date"><space/>January–February 2002<space/></arg><arg name="pmid"><space/>11782820<space/></arg><arg name="doi"><space/>10.1097/00045391-200201000-00010<space/></arg><arg name="last2"><space/>Ginsberg<space/></arg><arg name="last3"><space/>Barkin<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="title">Strategy to Eliminate Pethidine Use in Hospitals</arg><arg name="journal">Journal of Pharmacy Practice and Research</arg><arg name="volume">38</arg><arg name="issue">2</arg><arg name="year">2008</arg><arg name="pages">88–89</arg><arg name="url">http://jppr.shpa.org.au/lib/pdf/2008_06/2008_06_Editorials.pdf</arg><arg name="format">PDF</arg><arg name="author">MacPherson, RD; Duguid, MD</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Mather LE, Meffin PJ<space/></arg><arg name="title"><space/>Clinical pharmacokinetics of pethidine<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>352–68<space/></arg><arg name="date"><space/>September–October 1978<space/></arg><arg name="pmid"><space/>359212<space/></arg><arg name="doi"><space/>10.2165/00003088-197803050-00002<space/></arg><arg name="last2"><space/>Meffin<space/></arg></template></extension></tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids; and seizures, anxiety, mood changes and<space/><link><target>serotonin syndrome</target></link>.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Open-chain opioids</bold></tablecell></tablerow><tablerow><tablecell><link><target>Dextromoramide</target></link></tablecell><tablecell>Comes in tartrate salt and free forms; soluble in water (tartrate salt).</tablecell><tablecell>IM, IV, PO, rectal.</tablecell><tablecell>No data available.</tablecell><tablecell>Severe pain.</tablecell><tablecell>As per other opioids.</tablecell><tablecell>As per other opioids.</tablecell></tablerow><tablerow><tablecell><link><target>Dextropropoxyphene</target></link></tablecell><tablecell>Comes in free form, hydrochloride and napsilate salt forms; very soluble in water (HCl), practically insoluble in water (napsilate); degrades upon contact with light and air.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 80%; hepatic metabolism; half-life = 612 hours, 3036 hours (active metabolite).</tablecell><tablecell>Mild-moderate pain.</tablecell><tablecell>As per other opioids, plus ECG changes.</tablecell></tablerow><tablerow><tablecell><link><target>Dipipanone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; practically insoluble in water and ether, soluble in acetone and ethanol.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>PO, often in combination with<space/><link><target>cyclizine</target></link>.</tablecell><tablecell>Half-life = 20 hours.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Dipipanone 10mg + Cyclizine 30mg Tablets – Summary of Product Characteristics</arg><arg name="date">22 August 2012</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://www.medicines.org.uk/emc/medicine/26936/SPC/Dipipanone+10+mg+%2b+Cyclizine+30+mg+Tablets/</arg></template></extension></tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>Less sedating than morphine, otherwise as per morphine.</tablecell></tablerow><tablerow><tablecell><link><target>Levacetylmethadol</target></link></tablecell><tablecell>Comes in hydrochloride salt form.</tablecell><tablecell>As above plus nicotinic acetylcholine receptor antagonist.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding = 80%; half-life = 2.6 days.</tablecell><tablecell>Opioid dependence.</tablecell><tablecell>As per other opioids, plus ventricular rhythm disorders.</tablecell></tablerow><tablerow><tablecell><link><target>Levomethadone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; soluble in water and alcohol; degrades upon contact with light.</tablecell><tablecell>Mu opioid; NMDA antagonist.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>As per methadone.</tablecell><tablecell>As per methadone.</tablecell></tablerow><tablerow><tablecell><link><target>Meptazinol</target></link></tablecell><tablecell>Comes in hydrochloride salt form; soluble in water, ethanol and methanol, fairly insoluble in acetone; unstable at temperatures greater than 25&amp;nbsp;C.</tablecell><tablecell>Mixed opioid agonist-antagonist, partial agonist at mu-1 receptor; cholinergic actions exist.</tablecell><tablecell>IM, IV, PO.</tablecell><tablecell>Bioavailability = 8.69% (oral); protein binding = 27.1%; half-life = 2 hours; excretion = urine.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Holmes B, Ward A<space/></arg><arg name="title"><space/>Meptazinol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>285–312<space/></arg><arg name="date"><space/>October 1985<space/></arg><arg name="pmid"><space/>2998723<space/></arg><arg name="doi"><space/>10.2165/00003495-198530040-00001<space/></arg><arg name="last2"><space/>Ward<space/></arg></template></extension></tablecell><tablecell>Moderate-severe pain; perioperative analgesia;<space/><link><target>renal colic</target></link>.</tablecell><tablecell>As per pentazocine.</tablecell></tablerow><tablerow><tablecell><link><target>Methadone</target></link></tablecell><tablecell>Comes in hydrochloride salt form; soluble in water and ethanol; degrades upon contact with air and light and outside the temperature range of 15&amp;nbsp;C and 30&amp;nbsp;C.</tablecell><tablecell>Mu opioid; NMDA antagonist.</tablecell><tablecell>IM, IV, PO, SC.</tablecell><tablecell>Bioavailability = 36100% (mean: 7080%); protein binding = 8197% (mean: 87%); volume of distribution = 1.9-8 L/kg (mean: 4 L/kg); hepatic metabolism, mostly via<space/><link><target>CYP3A4</target></link>,<space/><link><target>CYP2B6</target></link><space/>and to a lesser extent:<space/><link><target>CYP2C9</target></link>,<space/><link><target>CYP2C19</target></link>,<space/><link><target>CYP2D6</target></link><space/>&amp;<space/><link><target>CYP2C8</target></link>; half-life = 5130 hours (mean: 2035 hours); excretion = urine (2050%), faeces.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lugo RA, Satterfield KL, Kern SE<space/></arg><arg name="title"><space/>Pharmacokinetics of methadone<space/></arg><arg name="journal"><space/>Journal of Pain & Palliative Care Pharmacotherapy<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>13–24<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16431829<space/></arg><arg name="doi"><space/>10.1080/J354v19n04_05<space/></arg><arg name="last2"><space/>Satterfield<space/></arg><arg name="last3"><space/>Kern<space/></arg></template></extension></tablecell><tablecell>Opioid addiction; chronic pain.</tablecell><tablecell>As per other opioids, plus QT interval prolongation.</tablecell></tablerow><tablerow><tablecell><link><target>Piritramide</target></link></tablecell><tablecell>Comes in free or tartrate salt forms.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>IM, IV, SC.</tablecell><tablecell>No data available.</tablecell><tablecell>Severe pain.</tablecell><tablecell>As per other opioids.</tablecell></tablerow><tablerow><tablecell><link><target>Tapentadol</target></link></tablecell><tablecell>Comes in free and hydrochloride salt forms.</tablecell><tablecell>Mu opioid and norepinephrine reuptake inhibitor.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 32%; protein binding = 20%; hepatic metabolism, mostly via<space/><link><target>CYP2C9</target></link>,<space/><link><target>CYP2C19</target></link>,<space/><link><target>CYP2D6</target></link>; excretion = urine (70%), faeces; half-life = 4 hours.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids; less likely to cause nausea, vomiting and constipation.</tablecell></tablerow><tablerow><tablecell><link><target>Tilidine</target></link></tablecell><tablecell>Comes in hydrochloride salt form; soluble in water, ethanol and dichloromethane; degrades upon contact with light.</tablecell><tablecell>Mu opioid metabolite,<space/><link><target>nortilidine</target></link>.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids.</tablecell></tablerow><tablerow><tablecell><link><target>Tramadol</target></link></tablecell><tablecell>Comes in hydrochloride salt form; freely soluble in water and methanol, insoluble in acetone; degrades at temperatures less than 15&amp;nbsp;C and 30&amp;nbsp;C and upon contact with light.</tablecell><tablecell>Mu opioid (mostly via its active metabolite,<space/><link><target>O-desmethyltramadol</target></link>) and<space/><link><target>serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link>.</tablecell><tablecell>IM, IV, PO, rectal.</tablecell><tablecell>Bioavailability = 7075% (oral), 100% (IM); protein binding = 20%; hepatic metabolism, via<space/><link><target>CYP3A4</target></link><space/>and<space/><link><target>CYP2D6</target></link>; half-life = 6 hours; excretion = urine, faeces.</tablecell><tablecell>Moderate-severe pain.</tablecell><tablecell>As per other opioids but with less respiratory depression and constipation. Psychiatric AEs reported. Serotonin syndrome possible if used in conjunction with other serotonergics.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold>Anilidopiperidines</bold></tablecell></tablerow><tablerow><tablecell><link><target>Alfentanil</target></link></tablecell><tablecell>Comes in hydrochloride salt form; freely soluble in ethanol, water, methanol; degrades upon contact with air and light.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>Epidural, IM, IV, intrathecally.</tablecell><tablecell>Protein binding = 90%; volume of distribution = small; half-life = 12 hours; hepatic metabolism, mostly via<space/><link><target>CYP3A4</target></link>; excretion = urine.</tablecell><tablecell>Procedural anaesthesia.</tablecell><tablecell>As per other opioids. Very sedating.</tablecell></tablerow><tablerow><tablecell><link><target>Fentanyl</target></link></tablecell><tablecell>Comes in free, hydrochloride salt, citrate salt forms; practically insoluble in water (free form), soluble in water (citrate salt form), freely soluble in ethanol and methanol; degrades outside the temperature range of 15&amp;nbsp;C and 30&amp;nbsp;C and upon contact with light.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>Buccal, epidermal, IM, IV, intrathecal, intranasal, SC, sublingual.</tablecell><tablecell>Bioavailability = 50% (buccal), 89% (intranasal); protein binding = 80%; hepatic metabolism, mostly via<space/><link><target>CYP3A4</target></link>; half-life = 219 min; excretion = urine (primary), faeces.</tablecell><tablecell>Moderate-severe pain (including labour pain); adjunct to anaesthesia.</tablecell><tablecell>As with other opioids, with less nausea, vomiting, constipation and itching and more sedation.</tablecell></tablerow><tablerow><tablecell><link><target>Remifentanil</target></link></tablecell><tablecell>Comes in hydrochloride salt.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>IV.</tablecell><tablecell>Protein binding = 70%; hydrolysed by blood and tissue esterases; half-life = 20 min; excretion = urine (95%).</tablecell><tablecell>Anaesthesia maintenance.</tablecell><tablecell>As with fentanyl.</tablecell></tablerow><tablerow><tablecell><link><target>Sufentanil</target></link></tablecell><tablecell>Comes in free and citrate salt forms; soluble in water, ethanol and methanol; degrades upon contact with light and temperatures outside 15&amp;nbsp;C and 30&amp;nbsp;C.</tablecell><tablecell>Mu opioid.</tablecell><tablecell>Epidural, IV, intrathecal, transdermal.</tablecell><tablecell>Protein binding = 90%; half-life = 2.5 hours; excretion = urine (80%).</tablecell><tablecell>Adjunct to anaesthesia and moderate-severe pain.</tablecell><tablecell>As with fentanyl.</tablecell></tablerow><tablerow><tablecell colspan="7" style="text-align:center;"><bold><xhtml:big>Other analgesics</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Acetanilide</target></link></tablecell><tablecell>No data.</tablecell><tablecell>Paracetamol prodrug.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Pain; fever.</tablecell><tablecell>Cancer; AEs of paracetamol.</tablecell></tablerow><tablerow><tablecell><link><target>Amitriptyline</target></link></tablecell><tablecell>Comes in free form and in hydrochloride and embonate salt forms; practically insoluble in water (embonate salt), freely soluble in water (HCl); degrades upon contact with light.</tablecell><tablecell>SNRI.</tablecell><tablecell>PO.</tablecell><tablecell>Hepatic metabolism, via<space/><link><target>CYP2C19</target></link>,<space/><link><target>CYP3A4</target></link>; active metabolite, nortriptyline; half-life = 927 hours; excretion = urine (18%), faeces.</tablecell><tablecell>Neuropathic pain; nocturnal enuresis; major depression; migraine prophylaxis; urinary urge incontinence.</tablecell><tablecell>Sedation, anticholinergic effects, weight gain, orthostatic hypotension, sinus tachycardia, sexual dysfunction, tremor, dizziness, sweating, agitation, insomnia, anxiety, confusion.</tablecell></tablerow><tablerow><tablecell><link><target>Dronabinol</target></link></tablecell><tablecell>Comes in free form; degrades upon contact with light.</tablecell><tablecell>Cannabinoid receptor partial agonist.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 1020%; protein binding = 9099%; volume of distribution = 10 L/kg; hepatic metabolism; half-life = 2536 hours, 4459 hours (metabolites); excretion = faeces (50%), urine (15%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Marinol (dronabinol) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/marinol-thc-dronabinol-342047#showall</arg></template></extension></tablecell><tablecell>Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.</tablecell><tablecell>Dizziness, euphoria, paranoia, somnolence, abnormal thinking, abdominal pain, nausea, vomiting, depression, hallucinations, hypotension, special difficulties, emotional lability, tremors, flushing, etc.</tablecell></tablerow><tablerow><tablecell><link><target>Duloxetine</target></link></tablecell><tablecell>Comes in hydrochloride salt form; slightly soluble in water, freely soluble in methanol; degrades upon contact with light.</tablecell><tablecell>SNRI.</tablecell><tablecell>PO.</tablecell><tablecell>Protein binding &gt; 90%; volume of distribution = 3.4 L/kg; hepatic metabolism, via<space/><link><target>CYP2D6</target></link>,<space/><link><target>CYP1A2</target></link>; half-life = 12 hours; excretion = urine (70%), faeces (20%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Cymbalta (duloxetine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/cymbalta-duloxetine-342960#showall</arg></template></extension></tablecell><tablecell>Major depression; generalised anxiety disorder; neuropathic pain.</tablecell><tablecell>Anticholinergic effects, GI effects, yawning, sweating, dizziness, weakness, sexual dysfunction, somnolence, insomnia, headache, tremor, decreased appetite.</tablecell></tablerow><tablerow><tablecell><link><target>Flupirtine</target></link></tablecell><tablecell>Comes as maleate salt. Chemically related to<space/><link><target>retigabine</target></link>.</tablecell><tablecell>Potassium channel (Kv7) opener.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Szelenyi I<space/></arg><arg name="title"><space/>Flupirtine, a re-discovered drug, revisited.<space/></arg><arg name="journal"><space/>Inflammation Research<space/></arg><arg name="volume"><space/>62<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>251–8<space/></arg><arg name="date"><space/>March 2013<space/></arg><arg name="pmid"><space/>23322112<space/></arg><arg name="doi"><space/>10.1007/s00011-013-0592-5<space/></arg></template></extension></tablecell><tablecell>PO, rectal.</tablecell><tablecell>Bioavailability = 90% (oral), 72.5% (rectal); protein binding = 80%; volume of distribution = 154 L; hepatic metabolism; half-life = 6.5 hours; excretion = urine (72%).</tablecell><tablecell>Pain;<space/><link><target>fibromyalgia</target></link>;<space/><link><target>Creutzfeldt-Jakob disease</target></link>.</tablecell><tablecell>Drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Devulder J<space/></arg><arg name="title"><space/>Flupirtine in pain management: pharmacological properties and clinical use.<space/></arg><arg name="journal"><space/>CNS Drugs<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>867–81<space/></arg><arg name="date"><space/>October 2010<space/></arg><arg name="pmid"><space/>20839897<space/></arg><arg name="doi"><space/>10.2165/11536230-000000000-00000<space/></arg></template></extension></tablecell></tablerow><tablerow><tablecell><link><target>Gabapentin</target></link></tablecell><tablecell>Comes in free and enacarbil salt forms; fairly insoluble in ethanol, dichoromethane, fairly soluble in water.</tablecell><tablecell>Binds to the 2-1 subunit of voltage gated calcium ion channels in the spinal cord. May also modulate NMDA receptors and protein kinase C.</tablecell><tablecell>PO.</tablecell><tablecell>Half-life = 57 hours.</tablecell><tablecell>Neuropathic pain; epilepsy.</tablecell><tablecell>Fatigue, sedation, dizziness, ataxia, tremor, diplopia, nystagmus, amblyopia, amnesia, abnormal thinking, hypertension, vasodilation, peripheral oedema, dry mouth, weight gain and rash.</tablecell></tablerow><tablerow><tablecell><link><target>Milnacipran</target></link></tablecell><tablecell>No data.</tablecell><tablecell>SNRI.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 8590%; protein binding = 13%: volume of distribution = 400 L; hepatic metabolism; half-life = 68 hours (L-isomer), 810 hours (D-isomer); excretion = urine (55%).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Savella (milnacipran) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 April 2014</arg><arg name="url">http://reference.medscape.com/drug/savella-milnacipran-345054#showall</arg></template></extension></tablecell><tablecell><link><target>Fibromyalgia</target></link>.</tablecell><tablecell>As per duloxetine, plus hypertension.</tablecell></tablerow><tablerow><tablecell><link><target>Nabiximols</target></link></tablecell><tablecell>Contains<space/><link><target>cannabidiol</target></link><space/>and<space/><link><target>dronabinol</target></link><space/>in roughly equal concentrations.</tablecell><tablecell>As per dronabinol.</tablecell><tablecell>Buccal spray.</tablecell><tablecell>Not available.</tablecell><tablecell>Neuropathic pain and spasticity as part of<space/><link><target>Multiple sclerosis</target><part>MS</part></link>.</tablecell><tablecell>As per dronabinol.</tablecell></tablerow><tablerow><tablecell><link><target>Nefopam</target></link></tablecell><tablecell>Comes in a hydrochloride salt form. Chemically related to<space/><link><target>orphenadrine</target></link>.</tablecell><tablecell>Unknown;<space/><link><target>serotonin-norepinephrine-dopamine reuptake inhibitor</target></link>.</tablecell><tablecell>PO, IM.</tablecell><tablecell>Protein binding = 73%; half-life = 4 hours; excretion = urine, faeces (8%).</tablecell><tablecell>Analgesia, especially postoperative;<space/><link><target>hiccups</target></link>.</tablecell><tablecell>Has antimuscarinic and sympathomimetic effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Evans MS, Lysakowski C, Tramèr MR<space/></arg><arg name="title"><space/>Nefopam for the prevention of postoperative pain: quantitative systematic review<space/></arg><arg name="journal"><space/>British Journal of Anaesthesia<space/></arg><arg name="volume"><space/>101<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>610–7<space/></arg><arg name="date"><space/>November 2008<space/></arg><arg name="pmid"><space/>18796441<space/></arg><arg name="doi"><space/>10.1093/bja/aen267<space/></arg><arg name="url"><space/>http://bja.oxfordjournals.org/content/101/5/610.full.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="last2"><space/>Lysakowski<space/></arg><arg name="last3"><space/>Tramèr<space/></arg></template></extension></tablecell></tablerow><tablerow><tablecell><link><target>Paracetamol</target></link></tablecell><tablecell>Comes in free form; practically insoluble in water, freely soluble in ethanol; degrades upon contact with moisture, air and light.</tablecell><tablecell>Multiple; inhibits prostaglandin synthesis in the CNS, an active metabolite,<space/><link><target>AM404</target></link>, is an<space/><link><target>anandamide</target></link><space/>reuptake inhibitor.</tablecell><tablecell>PO, IV, IM, rectal.</tablecell><tablecell>Protein binding = 1025%; volume of distribution = 1 L/kg; hepatic metabolism; half-life = 13 hours; excretion = urine.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Tylenol, Tylenol Infants' Drops (acetaminophen) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/tylenol-acetaminophen-343346#showall</arg></template></extension></tablecell><tablecell>Analgesia and fever reduction.</tablecell><tablecell>Hepatotoxicity; hypersensitivity reactions (rare), including<space/><link><target>Stevens-Johnson syndrome</target></link>; hypotension (rare; IV).</tablecell></tablerow><tablerow><tablecell><link><target>Phenacetin</target></link></tablecell><tablecell>No data.</tablecell><tablecell>Prodrug to paracetamol.</tablecell><tablecell>PO.</tablecell><tablecell>No data.</tablecell><tablecell>Analgesia and fever reduction.</tablecell><tablecell>Haematologic, nephrotoxicity, cancer and paracetamol AEs.</tablecell></tablerow><tablerow><tablecell><link><target>Pregabalin</target></link></tablecell><tablecell>Comes in free form.</tablecell><tablecell>As per gabapentin.</tablecell><tablecell>PO.</tablecell><tablecell>Bioavailability = 90%; half-life = 6.3 hours; hepatic metabolism; excretion = urine (90%).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McKeage K, Keam SJ<space/></arg><arg name="title"><space/>Pregabalin: in the treatment of postherpetic neuralgia<space/></arg><arg name="journal"><space/>Drugs & Aging<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>883–92<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19761281<space/></arg><arg name="doi"><space/>10.2165/11203750-000000000-00000<space/></arg><arg name="last2"><space/>Keam<space/></arg></template></extension></tablecell><tablecell>Neuropathic pain; anxiety; epilepsy.</tablecell><tablecell>As per gabapentin.</tablecell></tablerow><tablerow><tablecell><link><target>Propacetamol</target></link></tablecell><tablecell>Freely soluble in water; degrades upon contact with moisture.</tablecell><tablecell>Prodrug to paracetamol.</tablecell><tablecell>IM, IV.</tablecell><tablecell>No data available.</tablecell><tablecell>Analgesia and fever reduction.</tablecell><tablecell>As per paracetamol.</tablecell></tablerow><tablerow><tablecell><link><target>Ziconotide</target></link></tablecell><tablecell>Peptide.</tablecell><tablecell>N-type calcium-channel blocker.</tablecell><tablecell>Intrathecal.</tablecell><tablecell>Protein binding = 50%; half-life = 2.96.5 hours; excretion = urine (&lt;1%).<extension extension_name='ref' name="ZMSR"><template><target>cite web</target><arg name="title">Prialt (ziconotide) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">8 April 2014</arg><arg name="url">http://reference.medscape.com/drug/prialt-ziconotide-343378#showall</arg></template></extension></tablecell><tablecell>Chronic pain.</tablecell><tablecell>CNS toxicity (abnormal gait, abnormal vision, memory problems, etc.); GI effects.<extension extension_name='ref' name="ZMSR"></extension></tablecell></tablerow><tablerow><tablecell colspan="7" style="font-size:88%">Where indicates products that are no longer marketed.</tablecell></tablerow></table><heading level='2'>Novel analgesics</heading><paragraph>Some novel and investigational analgesics include subtype-selective<space/><link><target>voltage-gated sodium channel</target></link><space/><link><target>sodium channel blocker</target><part>blocker</part><trail>s</trail></link><space/>such as<space/><link><target>funapide</target></link><space/>and<space/><link><target>raxatrigine</target></link>, as well as multimodal agents such as<space/><link><target>ralfinamide</target></link>.<template><target>citation needed</target><arg name="date">October 2015</arg></template></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Audioanalgesia</target></link></listitem><listitem><link><target>Pain management</target></link></listitem><listitem><link><target>Patient-controlled analgesia</target></link></listitem><listitem><link><target>Pain in babies</target></link></listitem><listitem><link><target>Congenital insensitivity to pain</target><part>Congenital analgesia</part></link><space/>(insensitivity to pain)</listitem></list><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>35em</arg></template></paragraph><list type='bullet'><listitem><template><target>citation</target><arg name="contribution">[[s:Encyclopædia Britannica, Ninth Edition/Anodyne|Anodyne]]<space/></arg><arg name="title">''[[s:Encyclopædia Britannica, Ninth Edition|''Encyclopædia Britannica'', 9th ed.]], [[s:Encyclopædia Britannica, Ninth Edition/Volume II|Vol.&nbsp;II]]''<space/></arg><arg name="editor-last">Baynes<space/></arg><arg name="editor-first">Thomas Spencer<space/></arg><arg name="display-editors">0<space/></arg><arg name="publisher">Charles Scribner's Sons<space/></arg><arg name="location">New York<space/></arg><arg name="date">1878<space/></arg><arg name="ref">{{harvid|EB|1878}}<space/></arg><arg name="p">90<space/></arg></template>.</listitem><listitem><template><target>citation</target><arg name="contribution">[[s:1911 Encyclopædia Britannica/Anodyne|Anodyne]]<space/></arg><arg name="title">''[[s:1911 Encyclopædia Britannica|''Encyclopædia Britannica'', 11th ed.]], [[s:1911 Encyclopædia Britannica/Volume II|Vol.&nbsp;II]]''<space/></arg><arg name="editor-last">Chisholm<space/></arg><arg name="editor-first">Hugh<space/></arg><arg name="editor2-last">Phillips<space/></arg><arg name="editor2-first">Walter Alison<space/></arg><arg name="display-editors">0<space/></arg><arg name="publisher">Cambridge University Press<space/></arg><arg name="location">[[Cambridge, England|Cambridge]]<space/></arg><arg name="date">1911<space/></arg><arg name="ref">{{harvid|EB|1911}}<space/></arg><arg name="p">79</arg></template>.</listitem></list><paragraph><template><target>Analgesics</target></template><template><target>Major Drug Groups</target></template></paragraph><paragraph><template><target>Authority control</target></template><link><target>Category:Analgesics</target><part></part></link><link><target>Category:Pain</target></link><link><target>Category:Opioids</target></link><link><target>Category:Agnosia</target></link></paragraph></article>